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The potential of hybrid antibodies secreted by hybrid-
hybridomas in tumour therapy
M. Clark, L. Gilliland & H. Waldmann
Division ofImmunologj, Department of Pathology, University
of Cambridge, Camhridge CB2 IQP, UK.
The cell fusion of two Ig producing cell lines may result in
the codominant expression of all of the parental cell derived
Ig chains. For a cell making two Ig heavy chains and two Ig
light chains a random association of all chains results in 10
possible configurations of secreted antibody species. In
practice, not all the combinations of chains are observed at
the predicted frequencies for a random association but the
mixture is still usually complex. The interest in these anti-
bodies for therapy stems from the biological properties of
different species within the complex mixture. In addition to
the properties which depend upon the interaction of different
Ig isotypes with human effector mechanisms, there are
unique properties which result from the different binding
specificities for antigen. For example, certain species of
antibody are monovalent for binding to a given antigen.
Such monovalent antibodies with specificities for modulating
cell surface antigens seem to be more efficient than the
equivalent bivalent antibodies at lysing target cells with
complement. Another of the components of the mixture has
dual specificity for the two different antigens recognised by
the parental antibody types. These bi-specific antibodies are
capable of targetting drugs or toxins to cells expressing
appropriate cell surface antigens. Also of interest is the
ability of these bi-specific antibodies to induce very potent
tumour cell killing by activated T-cell blasts when the bi-
specific antibody is used to crosslink a component of the
T-cell receptor complex and a suitable cell surface antigen on
the target cell.
Leucocyte differentiation antigens
A. McMichael
Nuffield Department of Medicine, John RadelifA? Hospital,
Headington, Oxforld OX3 9DU, UK.
The results of the Third International Workshop and Con-
ference on Human Leucocyte Differentiation Antigens will
be presented. There are now a total of 50 named leucocyte
differentiation antigens. They have been defined by exchange
of monoclonal antibodies followed by comparisons of
binding, tissue staining, immunoprecipitation and functional
studies. For some of the antigens a function has been
Course organiser: A.A. Epenetos, Royal Postgraduate Medical
School and Hammersmith Hospital, London W12 OHS.
defined, others have no known function as yet. There are
problems in defining lineages on normal and abnormal cells.
Recombinant antibodies
L. Riechman & G. Winter
Medical Research Council Laboratory f otMolecular Biology,
Cambridge CB2 2QH, UK.
Immunotherapy has been used to treat pathogens and to
provide passive immunity. However, there can be problems,
i.e., the 'neutralising' antibody is only a small fraction of the
total immunoglobulin, human antisera may be infected with
viruses such as AIDS and hepatitis, and antibodies from
animal sources are recognised as foreign. These problems
should not occur if human monoclonal antibodies are used.
Unfortunately, the productron of human monoclonal anti-
bodies has proved difficult. Therefore, we have attempted,
via recombinant DNA technology to turn mouse or rat
monoclonal antibodies into 'human' antibodies.
At its simplest, variable regions from mouse or rat anti-
bodies conferring the antigen specificity can be combined
with human constant domains, resulting in a chimeric anti-
body having predetermined specificity and effector function
(Neuberger et al. Nature, 314: 268, 1985). Although such
antibodies may yet prove to be therapeutically useful, an
immune response of the recipient to mouse or rat variable
regions seems probable. Therefore the parts of the animal
variable domain conferring the antigen specificity have been
transplanted into the framework regions of a human variable
domain. We have applied this technique to construct
'humanised' antibodies binding a small hapten (Jones et al.
Nature, 321: 522, 1986) to lysozyme (unpublished) and to a
cell surface antigen, CAMPATH I (unpublished).
Coordinate elevation of serum markers in ovarian cancer but
not in benign disease
R.C. Bast, Jr., S. Knauf, A.A. Epenetos, M. Tanner,
T. Klug, J. Soper, W. Creasman, S. Gall, R.C. Knapp.
V. Zurawski, Jr., J. Schlom, D. Kufe & R.E. Ritts
Duke University Medical Ceniter, Du-ham, NC,- University of
Rochester, Rochester, NY, USA; Hammersmith Hospital,
London, UK; Centocor, Malvern, PA; National Cancer
Institute, Bethesda, MD; Dana Farber Cancer Institute,
Bostoni, MA; Majo Clinic, Rochester, MN, USA.
Effective screening for occult ovarian cancer requires tests
that are both sensitive and specific. Data so far suggests that
CA-125 is elevated in most patients with ovarian cancer. As
a single test, however, CA-125 is not sufficiently specific to
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permit cost effective screening of an apparently healthy
population. In order to develop a more specific screening,
multiple serum markers have been assayed with a panel of
sera from 51 ovarian cancer patients and from 50 individuals
with benign disease whose serum CA-125 levels exceeded
35 U ml-t. Among the patients with ovarian cancer, ele-
vations of CA-125 (>65Uml-1) were observed in 63%,
CA15-3 (>3OUml-1) in 590o, TAG 72.3 (>lOUml1-) in
470, placental alkaline phosphatase (PLAP) in 310%,
HMFG1 in 76%, HMFG2 in 63% and NB/70K in 57%. All
patients with elevated CA-15-3 or TAG 72.3 also had a CA-
125 >35Uml-I. Among the 50 'false positive' sera selected
from 4,947 donors, CA-125 was >35% in 100%, NB/70K
was elevated in 62%, TAG 72.3 in 6% and CA-15-3 in 2%.
PLAP also appeared quite promising in that elevated enzyme
levels were not found in the 'false positive' group. HMFG1
was elevated in 26% and HMFG2 in 12%. Among ovarian
cancer patients with CA-125 >65Uml- 1, TAG 72.3 or CA-
15-3 was elevated in 83%. In the 'false positive' group, only
5% of patients had elevations of one or other marker.
Prospective studies are required to test whether serum
markers in combination will prove sufficiently specific to
justify their use in individuals at risk for ovarian cancer.
Radiolabelled monoclonal anti-CEA antibodies and fragments
in colon carcinoma - diagnostic and therapeutic approach
J.P. Mach, J. Pettavel, A. Bishop-Delaloye & B. Delaloye
Institute ofBiochemistri', University of Lausanne, CA 10066
Epalinge and Div. of Nuclear Mcdicine, CH-1011 Lausanne,
Sivitferland.
Thirty-one patients with known colo-rectal carcinoma were
injected with 1-123 labelled F(ab')2 or Fab (n = 17) fragments
from monoclonal antibodies (MAb) anti-CEA. Patients were
examined by ECT at 6, 24 and sometimes 48 h after injection
using a rotating dual head scintillation camera. As recently
reported (Delaloye et al., J. Clin. Invest, 77, 301, 1986), all
23 primary tumours and local recurrences except one were
clearly visualised on at least two sections of different tomo-
graphic planes. Interestingly, 9 of these patients had almost
normal circulating CEA levels and 3 of the visualised
tumours weigh only 3 to 5 g. Following encouraging pre-
liminary results of tumour therapy in nude mice, showing
that anti-CEA MAbs labelled with therapeutic doses of 1-131
could inhibit the growth of human colon carcinoma xeno-
grafts or provoke tumour regression. Seven patients with
liver metastases of colon carcinoma were injected into the
hepatic artery with MAbs anti-CEA labelled with 100 mCi
1-131. We observed no side effects and good localisation of
1-131 MAbs in liver metastases as documented by ECT, but
we have not yet obtained definite evidence of tumour
regression.
The use of immunocytochemistry in surgical pathology
G.W.H. Stamp
Department of Histopathology%, Hanmnmersmith Hospital,
Lonlon W12 OHS, UK.
Immunocytochemistry has now established itself as a valuable
procedure in surgical pathology. A variety of antibodies,
both polyclonal and monoclonal are in use, and they are
usually well characterised and commercially available. The
illustrated examples are arbitrarily grouped into lympho-
reticular markers, cell membrane antigens such as HMFG1
and 2, cytoskeletal components (intermediate filaments and
actin), enzymes (NSE, prostatic acid phosphatase, PLAP),
cytoplasmic protein (e.g. S-100), extracellular base membrane
components (collagen type 4 and laminin), 'appropriate'
cell products (peptide hormones, thyroglobulin, myoglobin,
factor VIII-related antigen) and 'inappropriate' products
including 'tumour markers' (CEA, AFP, HCG hormones).
Problems arising from inadequately prepared material and
technical aspects leading to possible misleading results are
considered, and the necessity for close liason between the
referring clinician and surgical pathologist is emphasised.
Monoclonal antibodies at EM level
J. Polak
Department of HistochemistrV, Royal Postgradluate Me(lical
School, Hammnersms1ith Hospital, Lonclon W12 OHS, UK.
The ability to monitor cellular events and to identify,
morphologically, sub-cellular components involved in par-
ticular processes has greatly advanced since the advent of
monoclonal antibodies and their use in electron immuno-
cytochemistry. For instance, using simultaneous monoclonal
and polyclonal antibodies (to proteins and enzymes capable
of monitoring intracellular pH) on specially prepared tissues
it is now possible to visualise intracellular pathways involved
in protein synthesis.
The demonstration of co-existence of several substances
(e.g., active peptides) in a single cell has been greatly aided
by the use of monoclonal and polyclonal antibodies in
combination. For light microscopical studies, different
reaction products are revealed by the use of differently
coloured chromagens. For electron microscopy, monoclonal
and polyclonal antibodies are labelled with gold particles of
different sizes and are used on ultra-thin sections (the on-
grid immunolabelling or post-embedding method).
Low numbers of binding sites on cellular membranes can
now be visualised at the electron microscopical level, by the
use of specific monoclonal antibodies to receptors or by the
construction of divalent forms of antigens that can react
with the receptor and subsequently to a monoclonal
antibody. Again, the reaction is revealed by gold labelling
procedures.
Results of 1st international workshop on small cell lung cancer
antigens
P.C.L. Beverley, L.G. Borbrow & R.L. Souhami
ICRF Human Tumiour Imnmunolog, Group, UniversitY College
Hospital, Radiotherapy Departnwent, Univ,ersity College
Hospital, London? WCIE, UK.
The workshop used methods, developed in three inter-
national workshops on leucocyte differentiation antigens, to
group together clusters of monoclonal antibodies (mAbs)
with similar reactivity. Antibodies submitted to the work-
shop were coded and sent to participating laboratories which
were requested to carry out immunohistological, immuno-
cytochemical or FACS analysis on a range of tissues or cell
lines. Data from these studies was used to perform a
computerised cluster analysis. The results show that methods
developed by FACS analysis of mAbs to leucocyte antigens
can be applied to solid tumours. We have detected a cluster
of 12 mAbs reacting with SCLC which also reacts with
neuronal cells. Other smaller clusters of mAbs have also
been detected. The method provides a basis for identifying
and classifying antigens of any cell type and allows compari-
sons of different antibodies to be made in an unbiased
fashion. In relation to small cell carcinoma of the lung, it
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useful in the classification of lung tumours and might have a
future role in diagnosis or therapy.
J. Burchell, S. Gendler, A. Girling &
J. Taylor-Papadimitriou
Dynamics of antibody transport and internalisation
F. Matzku
Institute of Nuclear Meclicine, German Cancer Research
Centre, Heidelberg, FRG.
Antibody transport into target tissues and cells is determined
by the biology of the antigen and by the structure of the
MAb. Experiments using radiolabelled MAbs were carried
out with cultured melanoma, lymphoma and sarcoma cells,
and with athymic or competent animals bearing human or
rodent tumour transplants. Biodistribution studies were done
by immunoscintigraphy and whole body autoradiography.
Internalisation into cultured cells was observed with 3/15
MAbs, which, according to metabolic requirements and the
influence of bivalency, followed at least two different
mechanisms. Complete internalisation of any type of
externally bound MAb would invariably be achieved by anti-
lgG antibodies. Yet, induced and 'spontaneous' internal-
isation were directed into different cellular compartments. In
iio accumulation in tumours depended on rapid clearance,
as achievable with fragments. With an anti-lymphoma MAb,
biodistribution was greatly influenced by the fact that
antigen-positive normal and malignant cells showed
functionally different internalisation in 4itro and in lil'o.
Penetration into solid tissue was very limited with intact
IgG, large areas of the nodes being left cold, but was
gradually facilitated with fragments. Surprisingly, accumu-
lation in haematogenous or lymphatic metastases was
inversely correlated to size, suggesting preferential accumu-
lation in nascent processes with putatively better blood
supply.
Imperial Cancer Research Funcd, PO Box 123, Lonclon
WC2A 3PX, UK.
The most highly immogenic component of the human milk
fat globule membrane is a large molecular weight mucin
(>400kd) which is also secreted into human milk. Further-
more, many of the tumour associated antigens, defined by
monoclonal antibodies (MAb), are carried on molecules that
are at the very least immunologically related to the milk
mucin. Indirect evidence following the reaction of a MAB,
HMFG2, with breast cancer cell lines suggests that the
mucin produced by cancer cells may be aberrantly glyco-
sylated. To explore this possibility, we have purified the milk
mucin, deglycosylated it and produced MAbs to the mucin
protein core. One of these antibodies, SM-3, reacts with 910%
of breast carcinomas. Preliminary results show that it also
reacts with carcinomas derived from other tissues. However,
SM-3 shows little or no reactivity on pregnant and lactating
breast, normal resting breast and benign breast tumours. It
appears that this MAb is reacting with a protein determinant
which is masked in normal cells but which is exposed,
perhaps due to aberrant glycosylation in tumour cells. SM-3
and other MAbs to the mucin core protein have also been
used to screen gtl 1 expression library and cDNA clones
coding for part of a mucin gene.
Use of monoclonal antibody 47D10 to monitor circulating
tumour antigens
M.K. Ho, W.P. Carney, H. Rabin & M. Sullivan
Cloning the cDNA for the core protein of a breast cancer
associated mucin recognised by antibodies to the milk fat
globule
S.J. Gendler, J. Burchell, T. Duhig, A. Girling, R. Millis &
J. Taylor-Papadimitriou
Inmperial Cancer Research Funid, PO Bo-x 123, London
WC2A 3PX, UK.
Human mammary epithelial cells secrete and express on their
surfaces, complex mucin glycoproteins of molecular weight
> 250 kd. Attention has recently been focused on these
molecules, since many of the antibodies (among them
HMFG1 and 2) selected for their reaction with differen-
tiation or tumour-associated molecules, react differently with
epitopes carried on these mucins. To study the regulation
and analyse their molecular nature, we undertook to clone
the gene for the core protein including SM-3, to select 7
cross-reacting clones from an expression library made from
the breast cancer cell line MCF-7. Tissue specific expression
of the gene is confirmed by the observation that mRNA is
detected in breast epithelial cells but not in fibroblasts,
carcinosarcoma or lymphoblastoid lines. Restriction enzyme
analysis of human genomic DNA reveals extensive poly-
morphism which correlates with the polymorphism observed
at the protein level. The availability of a eDNA coding
for an epithelial-specific and tumour-associated mucin core
protein will enable us to predict structure and to study the
regulation of this molecule which is implicated in malignancy
by virtue of its expression in nearly all breast tumours.
E.I. dii Pont dte Nenmour-s anid CompanY, No. Billerica, MA
01862, USA.
A mouse monoclonal antibody (MAb) 47D10 was produced
against the human lung carcinoma line, A549. Immunohisto-
chemical studies showed that MAb 47D10 was reactive with
57-95% of carcinomas derived from lung, breast, colon,
pancreas. Staining was most intense with tissues from
pancreatic and lung tumours. The antigen defined by MAb
47D 10 was a glycoprotein of 67-97 kd on the surface of
A549 cells. The extracellular form of the antigen showed a
lower molecular weight of 60-80kd. To determine whether
the 47D10 antigen was shed into the circulation by tumours
in ilivo, a competitive ELISA was used to examine a panel
of >260 serum samples. Circulating 47D10 antigens were
found in sera of patients bearing breast, colon, pancreatic,
ovarian and lung tumours. Even though immunohisto-
chemical studies indicated strong reactivity of 47D10 MAb
with lung carcinoma, relatively low levels of circulating
antigen were detected in sera from patients with lung
tumours. In contrast, >750o of sera from patients with pan-
creatic and ovarian tumours showed elevated levels of 47D10
antigens as compared to normal controls. Sera from patients
with breast carcinoma could be differentiated from those
with breast fibrocystic disease with a sensitivity of 700o and
specificity of 880%. Furthermore, colorectal cancers with
hepatic metastases showed significantly (P<0.0001) higher
levels of 47D10 antigens than those with no hepatic involve-
ment. Therefore, quantitation of circulating 47D10 antigens
may be useful for monitoring of patients with pancreatic,
ovarian, breast and colorectal cancers.
Development and characterisation or monoclonal antibodies to
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Construction and expression of a tumour specific
murine/human chimeric antibody.
G.P. Moore
Integrated Genetics Inc., Framingham, MA, USA.
Variable region exons were cloned from heavy and light
chain Ig genes of a murine hybridoma which secretes a
human tumour-specific monoclonal antibody. These were
fused to human R and LI constant region exons and
transfected into myeloma cells which secreted the resultant
chimeric antibody. A series of experiments demonstrated that
the chimeric antibody retained specificity for tumour antigen
while acquiring various human characteristics. Moreover, the
chimeric antibody was immunologically distinct from the
murine MAb. Production of the chimeric antibody in
myelomas was amplified 25-fold by cloning the fusion genes
adjacent to the gene coding for dihydrofolate reductase and
selection in methotrexate. The chimeric antibody was shown
to bind to human tumours implanted in mice with
pharmacokinetics identical to those of the murine mono-
clonal antibody. These results suggest that genetically
engineered monoclonal antibodies may, in the future, be
clinically useful replacements for Igs produced by murine
hybridomas.
Expression of functional mouse antibody directed against
hPLAP in non-lymphoid cells
V. Feys, P. de Waele, A. Van de Voorde, P. Casneuf &
W. Fiers
Laboratory of Molecular Biology, State University of Ghent,
9000 Ghent, Belgium.
A mouse hybridoma cell line was isolated producing mono-
clonal antibodies (IgG2b, K) against the tumour-associated
marker human placental alkaline phosphatase (hPLAP). The
mRNAs coding for the heavy and light chains were cloned
as cDNA copies. Detailed restriction analysis and nucleotide
sequencing confirmcd the IgG2B isotype. These genes were
then separately inserted into the eukaryotic expression vector
pSVd2-3tss+, a derivative of pSV-BG, under control of the
SV40 early promoter. We obtained expression of a
functional anti-hPLAP mouse antibody in a COS transient
expression system and in a CHO permanent expression
system. Both genes were introduced with the calcium
phosphate technique in COSI cells, and 72 h after trans-
fection, lOngml- functional antibodies could be detected in
the supernatant. Western blot analysis revealed that the
molecular weight was identical with that of the mouse
antibody isolated from the hybridoma cell line. Permanent
CHO cell lines secr-eting 100ngml- 1 functional antibodies
were established upon transfection of CHO (dhfr-) cells with
the plasmids containing the H and L cDNAs and the
plasmid pAdD26SV-(A)-3 carrying the mouse dihydrofolate
reductase (dhfr) gene. These results indicate that not only
lymphoid cells, but also non-lymphoid cells, are capable of
synthesis and assembly of immunoglobulin chains that are
immunologically competent. A plasmid construction in
which we inserted a stop codon-containing sequence immedi-
ately following the hinge region of the H-chain cDNA
sequence yielded immunocompetent F(ab')2 molecules upon
transfection of COS or CHO cells.
Human monoclonal antibodies to colonic antigens
C. Yiu, L. Baker, C.G. Clark and M.J. O'Hare
Departnment ofSurgery, University College London,
WCIE 6JJ; Institute of Cancer Research, Royal Marsden
Hospital, Sutton, Surrey SM2 5PX, UK.
Despite much effort over the past 5 years, there remain
difficulties in obtaining human monoclonal antibodies of
pre-defined specificity. These include both low hybrid yields
and hybrid instability as well as poor tumour localisation in
vivo. Thus, collectively only about 100 human antibodies
with defined reactivities to antigens of all types have been
reported to date. In parallel with studies on a rat colonic
tumour model, we have attempted to identify human anti-
bodies from fusions of lymph nodes from patients with
colorectal cancer and patients with inflammatory bowel
conditions. We have used both our own HMy2 (Edwards et
al., Eur. J. Immunol., 12: 641, 1982) and the UC-729-6
(Glassy et al., Proc. Natl Acad. Sci. USA, 80: 6327, 1983)
cell lines. We have also derived a variant which can be used
to generate human hybridomas in high yield under serum-
free conditions from the outset. However, attempts to
increase hybrid yields with electrofusion techniques were
unsuccessful. A total of 1,500 human hybrids have been
prepared from 45 patients, but only 6 react strongly with
colorectal tumour membrane preparations.
Developments in radiochemistry
C.F. Meares, S.V. Deshpande, S.J. DeNardo &
D.A. Goodwin
Departments ofChemistry and Nuclear Medicine, University
of California, Davis, CA 95616, USA.
The attachment of radioactive metals to monoclonal anti-
bodies, for use in the diagnosis and treatment of cancer, is
an exciting development. A problem that applies particularly
to antibody-chelate conjugates is the accumulation of radio-
activity in the liver. Using a monoclonal antibody against
indium-L-benzyl-EDTA chelated, we have shown that practi-
cally all of the radioactive indium which is passed through
the liver and into the urine remains in the form of indium
benzyl EDTA chelated. Further, we have found that at least
the majority of the radioactive indium remaining in the liver
is still chelated to benzyl EDTA residues. This indicates that
it may be possible to use metabolically cleavable linkages
between antibody and chelate in order to reduce liver
activity. We have compared linkages consisting of (I) a
simple disulfide, (2) a simple diester, and (3) the peptide
(Ala-Leu)2-Gly. These three linkers lead to quite different
organ distribution and clearance of indium- 111 in mice. For
the disulfide linkage, indium is rapidly translocated to the
intestines; for the ester linkage, part of the radioactivity
rapidly clears through the urine in the first 24h, but the
concentration of indium in the liver at 24h is not greatly
reduced; for the peptide linkage, clearance is slow and high
levels of indium in the liver are observed. An alternative
approach to reducing liver levels involves administering the
indium-l 11 chelate in low molecular weight form, after a
pre-targetting treatment with an antibody or other protein
which can bind the small indium chelate. In this case very
low liver levels may be obtained.ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 513
Advances in radioimmunolocalisation with pre-clinical and
clinical applications
D.J. Hnatowich, F. Virzi & M. Rusckowski
Department ofNuclear Medicine, University ofMassachusetts
Medical Center, Worcester, MA, USA.
Clinical and pre-clinical studies using radiolabelled anti-
bodies are currently in progress at the University of
Massachusetts. In one investigation, the pharmacokinetics
of the 19-9, OC-125 and 10-3D2 antibodies (Centocor Corp)
radiolabelled with In-l11 for imaging is being measured in
patients. Despite identical protocols, significant differences
in in vivo behaviour have been observed among these anti-
bodies. For example, liver levels of In-l 11 following adminis-
tration of labelled 19-9 were almost twice that of OC-125
and whereas these levels were constant throughout for both
antibodies, in the case of 10-3D2, liver levels decreased
uniformly. A second clinical investigation has determined
the biodistribution in patients of OC-125 radiolabelled with
Y-90, a pure beta emitter. Five patients undergoing second-
look surgery for ovarian cancer were administered a tracer
dose of labelled antibody i.p. and tissue samples obtained for
counting. The results show that bone marrow will be the
dose limiting organ but since tumour/normal tissue ratios of
up to 25 were observed, it is likely that therapeutic efficacy
will be ultimately established in subsequent high dose
studies. Finally, the in vivo use of avidin and biotin is under
consideration for imaging and therapeutic applications as a
means of improving the localisation of radioactivity in the
target. Antibodies have been conjugated with avidin and
administered to animals before the administration of DTPA-
coupled biotin radiolabelled with In-111. Using a model in
which the target consisted of conjugated beads deposited in
the peritoneum of mice, it has been shown that target:non-
target radioactivity ratios may be significantly increased
compared to conventional procedures.
Progress and problems of radioimmunolocalisation
J.F. Chatal
INSERM U211, Nantes, France.
Progress in immunoscintigraphy depends on several
immunological, radiochemical and methodological variables.
The criteria of antibody efficiency include strong affinity,
recognition of a great number of antigens sites per target cell
and good immunohistochemically-assessed specificity. An
anti-GD2 antibody (produced by Cheung, Cleveland, USA)
meets this criteria. Initial immunoscintigraphic results after
radioiodination have been excellent, with contrasts which
appear to be markedly greater than with other currently used
antibodies. The choice of radionuclide is also important.
After an initial phase of clinical studies with iodine-131, the
tendency now in antibody labelling, is to use indium-l 11,
which is more stable in vitro and in vivo. Comparative
distributions in patients with tumours show increased
tumour uptake and higher tumour-to-tissue ratios with
indium-l 1. However, the high liver uptake hinders interpre-
tation of upper abdominal images. Finally, regardless of the
radionuclide used, the limiting factor of immunoscintigraphy
remains the tumour-to-nontumour ratio which is usually too
low to provide good scintigraphic contrast. Among the
methods capable to improving contrast, SPECT is probably
the best. Its use in comparison with that of planar scinti-
graphy has not yet been clearly demonstrated and compara-
tive clinical studies are under way to determine the roles of
the two detection methods. In terms of its clinical value,
immunoscintigraphy has already shown its complementarity
to other conventional diagnostic methods.
Correlation of vascular permeability (VP) and tumour blood
flow (BR) with antibody uptake in a renal cell carcinoma
(RCC) xenograft
H. Sands, P.L. Jones, S.A. Shah, D. Palme & R.L. Vessella
Dupont, N. Billerica, MA; University of Minnesota, USA.
The specific uptake of 125-I-A6H antibody by xenografts of
the RCC in the athymic mouse was considerably greater
than that seen for other human tumour xenografts and their
associated antibodies. The A6H-RCC model also demon-
strated both greater localisation indices and absolute amount
of antibody bound than did the B6.2-Clouser model. Several
physiological factors were studied to assess whether they
might play a role in this greater specific uptake. VP was
determined by measuring the amount of 125-I-BSA and 131-I
nonspecific IgCl extravasated out of the vasculature during
one hour. BF to the tumour was determined using the 86-Rb
method. BF and VP were found to be greater in the RCC
xenografts than in CL tumours. Differences in VP were
dramatic, showing the vasculature of the RCC xenograft was
twice as permeable as that of the CL tumour. Animals
bearing RCC or CL xenografts were injected with a
monoclonal antibody to human major histocompatibility
complex (125-I-anti-HLA). Tumour uptake of 125-I-anti-
HLA was found to be 5 x greater in RCC than CL
xenografts. These results, therefore, suggest that the differ-
ences seen in the physiological factors can account for some
of the greater specific 125-I-A6H uptake by the RCC.
Therapeutic use of radiolabelled monoclonal antibodies by
systemic and locoregional administration
P. Riva, G. Paganelli, G. Moscatelli, S. Benini
Ist Oncol Romanagnolo- Nuclear Medicine Department,
M. Bufalini Hospital, Cesena, Italy.
Eleven patients (2 breast, 2 lung, 3 colon, 4 ovary tumours),
with advanced disease, were selected for therapeutic appli-
cation of 1-131-labelled MOAbs following failure of chemo-
therapy or radio-therapy. We used antibodies HMFG1,
HMFG2, PLAP, AUAI (kindly supplied by Dr Epenetos-
London), F023C5 (Sorin Biomedica - Italy), and 494/32
(Behring- RFG). Antibody doses ranged between 10 and
30mg, and the 1-131 dose ranged between 50 and 150mC. In
3 cases the MOAbs were administered i.v., whilst in 8
patients, the i.p. or i.pl. route was selected. No side effects
were observed. All patients developed antimouse antibodies.
The effective half-life of administered radioantibodies ranged
between 30 to 70h. The calculated dose delivered to tumour
was 18-52Gy. The clinical results, at present (follow-up
between 3 and 18 months) can be summarised as follows: I
complete remission, 3 partial remissions, 4 static disease and
3 progressive diseases. These therapeutical trials appear
promising and suggest a more systematic use of this treat-
ment in order to collect more conclusive data.
Preparation and biodistribution of Indium-1ll labelled chelate
immunoconjugates of a monoclonal antibody to
carcinoembryonic antigen
D.K. Johnson, D.A. Westerberg, P.L. Carney,
G.A. Sumerdo, P.E. Rodgers & S.J. Kline
Abbott Laboratories, Abbott Park, IL 60064, USA.
Novel bifunctional derivatives of the chelating agents
ethylenediaminetetraacetic acid (EDTA) and diethylene-
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cyanatobenzyl moiety is attached at a methylene carbon
atom of one carboxymethyl arm of the chelator, have been
synthesised. These derivatives were used to prepare immuno-
conjugates of an IgGI monoclonal antibody to carcino-
embryonic antigen (CEA). The resulting reagents showed no
aggregation and no loss of immunoreactivity relative to the
underivatized antibody, at substitution levels as high as 10
chelators per antibody molecule. Incubation for 30 min at
room temperature with commercially available sources of
indium-l 11 chloride consistently resulted in >95% radio-
chemical yields of labelled antibody, averting the need for
any post-labelling purification step. Biodistribution studies in
nude mice (n=5 per group) bearing a CEA-positive xeno-
graft (LS174T), revealed comparable tumour uptake for both
the EDTA and DTPA conjugates at 48 h post-injection
(20.9+4.2% IDg- I and 19.7+5.3% IDg- respectively)
but a significantly lower liver uptake from the DTPA
conjugate (3.9+0.8% IDg-1) compared to the analogous
EDTA conjugate (9.1 +3.8% IDg-', P<0.05 by Student
t-test). Liver uptake at 48 h post-injection in non-tumour
bearing Sprague-Dawley rats was also low for both conju-
gates, with no significant differences seen between the EDTA
conjugate (0.96+0.12% IDg- 1) and its DTPA analogue
(1.07+0.27% IDg-1). We conclude that the characteristics
of these chelator immunoconjugates, both in vitro and in
animal models, arc sufficiently encouraging to warrant
clinical trials of their utility in radioimmuno-
scintigraphic detection of CEA-producing tumours.
In vivo labelling of biotinylated anti-CEA monoclonal
antibodies by radioactive avidin
G. Paganelli, P. Riva, G. Deleide, A. Clivio, F. Chiolerio,
M. Malcovati & A.G. Siccardi
Ospedale Bufalini, Cesena, Sorin Biomedica, Saluggia, SPA
Milano, University of Milan, Italy.
Several tumour associated monoclonal antibodies persist
on the surface of tumour cells in vivo, with the best
tumour/background ratios being achieved 72-96 h post-
injection of radiolabelled Mab. We have developed a strategy
to target nuclides to tumour bound antibodies, at a time
when non-specific localisation has already been cleared,
using subsequent administrations of biotinylated Mab and of
nuclide-conjugated avidin. Preliminary experiments have
been performed in rabbits. Native avidin labelled with 131-I
and 111-In (as DPTA conjugate) was tested for its reactivity
with biotin and was found to be between 93-100%. Bio-
distribution studies after both i.v. and i.p. administrations of
the iodinated reagent showed a biological half-life of 24h.
The In-labelled reagent showed marked liver accumulation,
possibly due to indium transferrin exchange. Biotinylated
and non-bitinylated nitrocellulose targets were implanted in
the peritoneal cavity of 5 rabbits. Radioactive avidin,
administered i.p., accumulated on the biotinylated target at
least 10 times more efficiently than on the control target.
Labelling platelets with an indium labelled monoclonal
antibody
A.M. Peters, I. Loutfi, P. Lumley, N. Courtenay-Luck &
J.P. Lavender
Hamnmner.snmith Hospital, Londloni and Glaxo Group Research,
Ware, UK.
We have evaluated a new technique for labelling platelets
using In-lI-labelled monoclonal, IgGI, antibody (P256)
raised against the platelet surface glycoprotein, GlIblIla
(Imperial Cancer Research Fund, London). P256 was
labelled by coupling to DTPA followed by chelation of
In-111. In-111 uptake was 5-7mCi mg-1 P256. Platelet
function following exposure to P256 was tested by measure-
ment of spontaneous aggregation and aggregometry using a
whole-blood platelet counter (Ultra-flow 199). A platelet
receptor occupancy of 6% was the maximum that resulted in
spontaneous aggregation in platelet-rich plasma (PRP), com-
parable to that seen in the absence of P256. The antibody
can be shown to label platelets both in vitro and in vivo. The
FAB/2 fragment of P256 has also been shown to label
platelets in vitro. One normal volunteer and 12 patients with
suspected venous thrombus have been imaged with either
Indium-l 1 labelled P256 or its fragment. Localisation in
thrombus was seen in 5. This technique therefore promises
to be a simple specific method of platelet labelling.
Imaging of colon cancer with 1-131 human monoclonal IgM
J.A. Carrasquillo, R. Steis, M. Bookman, J. Smith,
Del Vecchio, J. Reynolds, P. Perentesis, R. McCabe,
M.V. Haspel, M. Hanna, D. Longo & S.M. Larson
DNM, CC, NIH, Bethesdca and BRMP, DCT, NCI, Frederick
and Bionetics Research, Rockville, MD, USA.
We have evaluated 2 different 1-131 labelled IgM human
monoclonal antibodies (HMoAb) for their ability to image
tumours and their pharmacokinetics when given in escalating
doses in I I pts with metastatic colon cancer. Seven pts
received 5 mCi and 8-108 mg of HMoAb 28A32 obtained
from a human-mouse hetero-hybridoma, and 4 pts received
5 mCi and 8-58 mg of HMoAb 16.88 obtained from a
transformed human lymphocyte. Both HMoAb react with a
colon carcinoma associated antigen. All pts had positive
immunohistology in a previously resected tumour biopsy.
The antibodies were labelled via the iodogen method at a
mean specific activity of 1. mCimg - with good retention
of immunoreactivity. All pts underwent an initial study with
8 mg of HMoAb followed by a second study at the higher
HMoAb dose 7 days later. Imaging was seen in 6/7 pts
receiving 28A32 and in 3/4 pts receiving 16.88. Initially
tumours appeared as 'cold' lesions with optimal contrast
between tumour and non-tumour after 5 days that persisted
up to 23 days. There was 29-38% of the dose in plasma at
24 h and a whole body clearance (T 1/2) of 1.5 days. No dose
dependent differences were observed in the pharmacokinetics
or tumour imaging. One patient had a positive skin test to
28A32 (but not 16.88) prior to receiving any HMoAb and
was excluded from imaging. No definite antibody associated
toxicity was observed. HMoAb IgM can be radiolabelled
with 1-131 and used safely and successfully to image sites of
metastatic colon cancer.
Tumour imaging of colorectal carcinoma with an anti-CEA
monoclonal antibody
M. Gasparini, M. Ripamonti, E. Seregni & G.L. Buraggi
Divisions of Nuclear Medicine and Experimental Oncology E,
Instituto Nazionale Tumori, Milan, Italy.
The 131-I-labelled anti-CEA monoclonal antibody (F023C5
Sorin Biomedica) was used in a preclinical in vivo study in
an animal model and in a clinical study in patients with
cancer. The results obtained with nude mice bearing a CEA-
producing colon carcinoma showed the antibody's speci-
ficity, and defined parameters for imaging in relation to the
dose and administration route. Initially, we performed a
pilot study at the National Cancer Institute of Milan on 48
patients with colorectal carcinoma. High sensitivity (>90%)
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and abdominal metastases. These data were confirmed in a
multicentre trial organised by the Italian National Research
Council on 300 patients with 700 tumour sites. We conclude
that this method may be of clinical value.
CA-125 and screening for ovarian cancer: Serum levels in
1,010 apparently healthy postmenopausal women
I.J. Jacobs, J. Bridges, I. Stabile, P. Kemsley, C. Reynolds &
D.H. Oram
Department of Obstetrics and Gynaecology, The London
Hospital, Whitechapel, London, UK.
One thousand and ten apparently healthy postmenopausal
female volunteers over 45 years of age and with a history of
amenorrhoea for greater than 12 months attended for veno-
puncture and pelvic examination. Serum samples were assayed
using the Abbott Laboratories CA- 125 radioimmunoassay
kit. The 90th, 95th and 98th centiles for serum CA-125 in
this group of postmenopausal women were 23.2, 26.3 and
30.85 U ml- respectively. Thirty-one women with CA-125
level >30 U ml- 1 proceeded to ultrasound scanning. Three
of these women underwent surgery following an abnormal
ultrasound scan of which 1 had no abnormality, 1 a fimbrial
cyst and the third a stage I B ovarian cancer. The other 28
had no abnormality on ultrasound scan and have been
followed up with 3 monthly serum CA-125 measurement and
repeat scans. In addition, 7 benign tumours found on vaginal
examination and confirmed by ultrasound scans were
removed at laparotomy. None of these 7 women had a
serum CA-125 > 30 U ml - 1.
We conclude that CA-125 has high specificity for ovarian
cancer when used to screen postmenopausal women. To
achieve maximal sensitivity the upper normal limit for serum
CA-125 in a screening programme for ovarian cancer incor-
porating the CA-125 assay and ultrasound scanning should
be set at 23 Uml-1. This would result in -10% of the
screened population requiring an ultrasound scan. The value
of the CA-125 assay for early diagnosis of ovarian cancer
warrants further investigation in a randomised controlled
study.
A phase I study using pan T lymphocyte-ricin A chain
immunotoxin to treat steroid resistant graft versus host disease
(GVHD)
V. Byers, N. Kernan, J. Henslee, R. Gingrich, B. Blazer,
R. Mischak, J. Kersey, R. O'Reilly, J. Thompson &
P. Scannon
Xoma Corp., Berkeley, CA; Sloan Kettering Institute, NY; U
Kentucky?; U Iowa and I. Minn., USA
A phase I clinical trial has been completed in which bone
marrow transplant recipients with grade II-IV steroid
resistant GVHD were treated with an immunotoxin con-
structed by linking monoclonal antibody XMMLY-H65,
directed against the CD5 antigen on human lymphocytes, to
ricin A chain (XMMLY-H65). Patients received up to 14
daily infusions of XMMLY-H65 in escalating doses. To
date, more than 14 evaluable patients have been accrued.
The treatment was well tolerated without noticeable toxicity.
The most consistent finding was a rapid drop in T-lympho-
cytes, which usually persisted throughout the course of
infusions. Target tissue clearing was seen early with skin,
during the first 2-5 days of infusion, and later with gut,
within the first week after completion of infusions.
Peripheral T-cells reappeared 1-3 weeks after treatment,
without recurrence of GVHD. Anti-immunotoxin antibodies
were present in some patients. We conclude that immuno-
toxin treatment represents a promising therapy for patients
with severe acute or chronic GVHD.
Studies with antibody/drug conjugates
T.F. Bumol
Lilly Research Laboratories, Indianapolis, IN, USA1
Murine monoclonal antibody KSI/4, which recognises an
epithelial/epithelial malignancy-associated antigen, has been
utilised as a targetting vehicle with covalently attached
vinca alkaloid moieties for the preclinical development of a
site-directed tumour therapy strategy. Two conjugates;
KSI/4-desacetylvinblastine (KSI /4-DAVLB, Lilly Serial
£LY256787) and KS1/4-desacetylvinblastine-hydrazide
(KSI/4-DAVLB-Hydrazide, Lilly Serial £LY203725) are
currently being considered as clinical trial candidates. These
agents represent different conjugation chemistry strategies
and both demonstrate in vivo efficacy in a number of pre-
clinical studies with human colon and lung adenocarcinoma
xenografts. Both agents display activity in models with
low tumour burden (90-100% tumour growth suppression
can be achieved), establishes tumours (measurable tumour
regressions) and experimental metastases (2-5 x increase in
mean survival time) with therapeutic index advantages over
conventional chemotherapy. Toxicology experiments in rats
and primates document that repetitive dose schedules can be
tolerated and that both conjugates are significantly less toxic
than corresponding dosages of free vinca alkaloids. KSI/4-
DAVLB and KS1/4DAVLB-hydrazide represent high and
low dose strategies for the application of these agents to
human oncology.
Clinical trials of immunotoxins for the treatment of solid
tumours
L.S. Spitler
Xomna Corp., Berkeley, CA 94710, USA.
We have initiated clinical trials of monoclonal antibody ricin
A chain immunotoxins XOMAZYME-MEL for therapy of
metastatic melanoma and XOMAZYME-COL for therapy
of metastatic colorectal cancer. A phase I trial of the
antimelanoma immunotoxin in 22 patients has been com-
pleted. The side effects were related to the dose of immuno-
toxin and were generally transient and reversible. These
included (1) a transient fall in serum albumin with an
associated weight gain, and oedema without proteinuria; (2)
malaise fatigue, myalgia, anorexia and fever; (3) a transient
decrease in voltage on electrocardiograms without clinical
symptoms, change in serial echocardiograms, or elevation of
creatine phosphokinase MB isozyme levels. Symptoms due
to allergic reactions were observed in 3 patients. There was
one complete response, lasting 26 months after a single
course of immunotoxin, and evidence of biological activity
of the immunotoxin in 9 additional patients. Localisation of
antibody and A chain to sites of metastatic disease was
demonstrated. A phase II multicentre trial of the
antimelanoma immunotoxin was conducted in 46 patients.
Thirty-five received a 5 day course and 7 patients received 3
or 4 day courses (total =42 patients). Review of data
indicates that the side effects were similar to those observed
in the phase I trial. Efficacy is also similar. Out of the 43
patients there were 3 partial responses and evidence of
biologic activity in 10. Side effects in the ongoing Phase I
trial of biologic activity in 10. Side effects in the ongoing
Phase I trial of colorectal cancer are similar to those
observed in the melanoma trial suggesting that they are due
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Immunological tailoring of monoclonal antibodies (MAb)
suited for immunotherapy of pancreatic carcinoma
K. Bosslet, H.U. Schorlemmer, G. Schulz & H.H. Sedlacek.
Research Lab of Behrwingwerke AG, D-3550 Marburg/Lahn,
FRG.
Four mechanisms may be involved in the potential action of
monoclonal antibody guided immunotherapy of pancreatic
carcinoma.
(a) MAb dependent cellular tumour cytotoxicity (ADCC).
(b) MAb dependent complement mediated cytolysis.
(c)
(d)
MAb induced anti anti idiotypes.
MAb mediated inhibition of pancreatic carcinoma cell
functions like endocytosis, lysosomal enzyme and super-
oxide anion secretion.
Mechanisms (a) and (b) are mediated by the isotype of the
MAb molecule whereas (c) and (d) are induced by the
idiotype. MAb BW 494 of IgGl isotype is able to mediate
functions described under (a) and (d). Using the sib selection
procedure combined with a highly sensitive ELISA for the
detection of spontaneous changes in the isotype from IgGl-
IgG2a, we were able to establish a panel of isotype switch
variants of MAb BW 494. The IgG2a switch variants had
the same epitope specificity as the parental IgGl MAb, but
learnt to perform human complement mediated cytolysis
with human pancreatic carcinoma cell lines very efficiently.
Clinical trials to evaluate whether MAb BW IgG2a might be
superior to MAb BW IgGI in the immunotherapeutie treat-
ment of human pancreatic carcinomas are in progress.
Immunotherapy of pancreatic cancer with monoclonal antibody
494/32
G. Schulz, R. Klapdor, M. Bulcher, R. Kubel,
K.H. Muhrer, H.P. Harthus, N. Madry & K. Bosslet
Res. Dept, Behringverke AG, 3550 Marburg; Dept oflnt.
Medicine, Univ. Hamburg; Dept of Surgery, Univ. Ulm; Dept
Surgery, Univ. Gieben, FRG.
The murine monoclonal antibody (MAb) 494/32 (BI 51.011)
directed against a pancreatic cancer associated glycoprotein
antigen was selected for a phase I/II therapy trial because of
cytotoxic (ADCC) in vitro killing of these tumour cells, and
inhibition of pancreatic cancer xenografts growth in nude
mice. Fifteen patients with advanced pancreatic cancer
received increasing doses of MAb (5-100mg) over a time
period from 5 to 10 days. In a second phase, 10 additional
patients were treated with an additional dose of 100mg
MAb followed by up to 13 daily infusions with 30mg MAb
(highest cumulative dose 490mg). During this treatment,
serum levels of murine IgG were raised to 43.3 igml-1. The
serum half life of murine IgG ranged from 3-4 days.
Repeated injections of high amounts of murine MAb were
well tolerated when given within the first 15 days. Most
patients (13/15) developed at that time, anti-murine anti-
bodies which resulted in anaphylactic reactions when therapy
was continued (I patient) or when it was repeated after some
weeks (3 patients). Two patients developed fatigue and a
neuritis-like syndrome, 1 week after the last IgG infusion
which resolved spontaneously by the next day. In some
patients it could be shown that the anti-murine response
was, in part, anti-idiotypic. Fifteen out of 25 patients were
eligible for evaluation of therapeutic efficacy. Two patients
(13.3%) responded with tumour regression documented by
reduction of liver metastases and primary tumour as assessed
by CT scan. This correlated with a decrease of tumour
markers (CA 19-9, CEA) and clinical improvement. One of
these patients is now in remission for 36 weeks. Four (26.6%)
additional patients with progressive disease stabilised. Ten
out of 15 patients are still alive. The median survival ol all
patients after diagnosis is 43 weeks.
Dosimetry for radiolabelled antibodies - macro or micro?
M.J. Myers
Hammer-smith Hospital, Loncon W12 OHS, UK.
Dosimetric calculations for the therapeutic use of radio-
labelled antibodies have usually involved macroscopic (so-
called MIRD formulation) assumptions about the distri-
bution of energy deposited within a tumour or organ. This
type of calculation probably suffices for gamma and for
moderately energetic beta radiation such as that from 1-131
or Y-90. When less conventional radionuclides, such as
Alpha and Auger electron emitters, are proposed as antibody
labels and significant amounts of emissions with ranges in
tissue of the order of individual cell dimensions can be
deposited at the cell surface then a different sort of calcu-
lation, microdosimetry, must be performed. This is because
the macro assumptions about the average amount of energy
deposited in each small amount of tissue no longer hold.
Practical dosimetry will probably involve both approaches
with macrodosimetry used to assess risk to normal organs
and microdosimetry for assessing potential damage to
targets. Promises of specific antibody targetting at the indi-
vidual cell must, however, be translated into reality for
developments in microdosimetry to be applicable.
Quantitative SPECT in nuclear medicine. Application in dose
planning for radionuclide therapy.
S.E. Strand & M. Ljungberg
Radiation Physics Department, University of Lund, Lund,
Swveden.
In nuclear medicine imaging, SPECT is being used with
increasing frequency for routine studies of different organs.
A new approach is to use quantitative SPECT for dose
planning in radionuclide therapy. Proper dose planning
requires an absolute qualification of the activity of the
therapeutic radiopharmaceutical uptake in different tissues.
In order to calculate the absorbed dose, the specific activity
(MBqg- 1) must be determined with high accuracy. Using
SPECT, the specific activity can be determined if the activity
in, and the volume of, the target can be estimated. An
essential parameter in SPECT images to consider is the
photon attenuation. A new method for attenuation corection
based on measured attenuation charts of the actual object
has been developed. Using the attenuation chart, the
emission image is corrected pixel by pixel for photon attenua-
tion. With this method, it is possible to reduce the margin
of error due to attenuation to less than e.g. 5% for 140 KeV
photons. By using quantitative SPECT with attenuation
correction, for dose planning in radionuclide therapy, it is
possible to calculate the absorbed dose to the target volume,
with a margin of error of < 10%.
Quantitation in 1-131 radioimmunotherapy using SPECT
S.J. Riggs, A.J. Green, H.J. Begent & K.D. Bagshawe
Cancer Research Campaign Laboratories, Dept of Medical
Oncology, Charing Cross and Westminster Medical School,
London W6 8RF, UK.
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used to deliver 1-131 specifically to the tumour. For the
effects of RIT to be clearly understood, it is necessary to
quantify the concentrations of the radionuclide in various
organs. Planar gamma camera imaging has been used in
previous studies but this leads to problems where there are
overlying organs or tissue. SPECT overcomes these problems
by providing a 3-dimensional representation of the activity
distribution. Planar imaging and SPECT were compared in
phantom studies and in patients receiving therapeutic doses
of 1-131-labelled anti-CEA. The method of Thomas et al.
(Radiol., 133, 465, 1979) was used for quantitation. From the
planar images for SPECT, back projection reconstruction
was used with attenuation correction. Scattered photons
were compensated for using data acquired simultaneously
from a secondary window. All data were obtained on an
IGE Gemini 700 gamma camera with a high resolution
400 KeV collimator. The limitations of SPECT quantitation
were examined using phantom studies and it was shown that
practical SPECT quantitation can be achieved in patients
given therapeutic doses of 1-131-labelled anti-CEA. This is
likely to be of value in dosimetry for RIT and other
treatments using 1-131.
Treatment of human tumour xenografts with 1-131-labelled
monoclonal antibodies
R. Senekowitsch, H. Glassner, G. Reidel, G. Mollenstadt,
H. Kriegel & H.W. Pabst
Department of Nuclear Medicine, TU and Department of
Nuclear Biology, GSF, Munich, FRG.
An iodinated monoclonal antibody (MAb) with a high
tumour deposition of >50% IDg- I and a long tumour
residence time with a half-life of 5 days was used for
treatment of human mammary tumour xenografts in nude
mice. The radiation dose received by the tumour xenografts
after injection of 2x7.4MBq of the tumour specific MAb
was calculated as 50Gy, by sequential scintigraphic follow
up of the injected animals. The therapeutic effect of the
activity resulted in a pronounced reduction of the tumour
diameter compared to animals injected with the same
amount of unlabelled MAb, 1-131-labelled non-specific MAb
or only saline. On histological examination of the tumour
tissue, large areas of necrosis and a high amount of pyknotic
cells could be detected. In some animals the remaining tissue
in the tumour at day 42 after injection could be identified as
only mouse connective tissue invading the human tumour
xenografts.
Advances in Neuro-Oncology
H. Coakham
Brcain Tumour Laboratory, Department of Neurological
Surgery, Frenchay Hospital, Bristol, UK.
Selected panels of MCAs recognising neuroectodermal
antigens, intermediate filament proteins, epithelial and leuco-
cyte antigens have been used in immunohistochemistry to
incrcase the diagnostic accuracy of brain tumours by 20% in
over 250 cases. Similarly, accurate diagnosis of tumour cells
in cerebrospinal fluid (CSF) has been achieved in 95% of
cases, resulting in important changes in management.
In vitro binding assay on tumour homogenates with 131-I-
specific and 125-I non-specific MCA show high 'dose
delivery' and specificity. However, i.v. injections produce
scintigraphic tumour images but result in low specificity and
indices and <0.005% injected dose delivered to tumour.
In contrast, administration of labelled MCA into CSF
pathways produces more specific tumour binding. Biological
responses and increased survival (1-2 years) were seen in 5/7
patients given antibody-guided therapy (11-50 mCi-131-I)
for neoplastic meningitis from medulloblastoma, lymphoma,
melanoma and pineoblastoma. All cases had relapsed after
optimum conventional therapy. No significant side effects
occurred. This approach may offer an alternative to the
prophylactic external beam radiation which is used to
achieve CSF 'clean up' in certain paediatric malignancies but
has adverse effects on CNS development.
Antibody guided diagnosis and therapy
A.A. Epenetos
On behalfofImperial Cancer Research Fund Oncology Group,
Royal Postgraduate Medical School, Hammersmith Hospital,
London W12 OHS; Imperial Cancer Research Fund
Laboratories, London WC2, UK.
Progress is continuously being made in the in vivo appli-
cations of monoclonal antibodies, with the introduction of
new pharmaceuticals, detailed pharmacokinetic studies and
evaluation of techniques for tumour imaging. Based on our
experience, we now recommend that for meaningful radio-
immunolocalisation, one should incorporate specific and
non-specific antibodies for tumour imaging.
Thirty-four patients with resistant ovarian cancer have
been treated with i.p. 1311-labelled antibodies (HMFGI,
HMFG2, AUAI, H17E2). There were no significant
responses in 7 patients with gross disease. There were 2
responses in 13 assessable patients with tumour nodules of
2cm in diameter. Out of 6 patients with microscopic disease,
5 are disease free with target follow-up being over 3 years.
A new phase I-II has been initiated using 90Y as radio-
label. Clinical pharmacokinetic studies have been performed
and encouraging responses with no toxicity have already
been observed. This new method of treatment appears to be
of value in patients with residual ovarian cancer.
Human immune responses: The full network
M. Ritter, N. Courtenay-Luck, G. Sivolapenko &
A.A. Epenetos
Departments of Clinical Oncology and Immunology, Royal
Postgraduate Medical School, Hammersmith Hospital, London
W12 OHS, UK.
Both patients and healthy controls have low serum levels of
IgM antibody rheumatoid factors which react with both
human and murine IgGI. These rheumatoid factors cause
the pre-existing human anti-mouse response.
After one therapeutic administrstion of murine antibodies,
patients develop antibodies which react with the Fc portion
of the murine immunoglobulin. Subsequent administrations
lead to the generation of both anti Fc and anti F(ab')2
antibodies. A component of the anti-F(ab')2 response is anti-
paratopic. These anti-paratopic or anti-idiotypic antibodies
(anti-id) reflect the internal image of tumour associated
antigens and in in vitro assays, block the binding of the
administered murine antibody to its antigen.
In those patients with anti-id' antibodies, antibodies with
binding specificities similar to the administered murine anti-
bodies are detectable. These are anti-id2 or anti-tumour
antibodies generated by either an anti-idiotypic network or
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Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid
antibodies induce tumour cell lysis by cytotoxic T-cells
S. Canevari, S. Menard, D. Mezzanzanica, S. Miotti,
S.M. Pupa, A. Lanzavecchia & M.I. Colnaghi
Instituto Na;ional Tuniori, Milan, Ita/' and Institutefir
Immunology, Basel, Switzerland.
In the perspective of therapeutic in vivo targetting for T-cell
attack, the monoclonal antibody (MAB) MOvI8, selected for
its restricted reactivity with human ovarian carcinoma and
an anti-T3 MAB, were used to produce heteroconjugates or
hybrid antibodies derived by the fusion of the relevant
hybridomas. The specificity and the activity of the bispecific
MABs were analysed by solid-phase RIA, immunofluor-
escence, competitive binding and a 51-Cr release assay on
the ovarian carcinoma cell line OVCA432 which expresses
the relevant tumour-associated antigen and on several
irrelevant tumour cell lines and normal cells. Both reagents
efficiently promoted, at nanomolar concentration, target cell
lysis by cytotoxic T-cell (CTL) clones. Although the pattern
of the tumour cell lines which were lysed was wider than
that predicted by the binding studies, further studies using a
more sensitive biochemical technique confirmed that the
specificity of the MABs is superior to heteroaggregates both
in purification recovery and storage stability. Peripheral
blood lymphocytes could also be used as cytolytic effectors,
provided that a suitable in vitro activation scheme was
adopted.
Tumour therapy with vinca alkaloids targetted by a
hybrid-hybrid monoclonal antibody recognising both CEA and
vinca alkaloids
puting an index of antigenic expression which took into
account the percentage of stained cells and the intensity of
staining. For the 3 antibodies, this index was respectively
166, 114 and 73. Nude mice were injected i.p. with 2 x 107
cells, and the peritoneal cavity became progressively lined by
tumour nodules before the animals died at 80+5 days. The
first biodistribution studies were performed with In-Il 1-
DTPA-OC125 antibody (In-OC125) injected i.p. in intact
form 50-60 days after i.p. grafting of the tumour cells. The
animals were sacrificed 2 and 24h after injection (5 mice for
each time period), and the results expressed as percentage of
injected dose g-1 (% IDg-1) and in tumour-to-organ ratios.
A nonspecific immunoglobulin labelled under the same con-
ditions (In-NS) was injected into the same number of mice.
With In-OC125 the % IDg-I in the tumour was 14.4+0.7
and 27.8 + 8.6 at 2 and 24h respectively; with In-NS the
percentage for the same time periods was 8.9+1.7 and
4.4+0.8. With In-OC125 the tumour/blood, tumour/liver
and tumour/kidney ratios were respectively 3.7 +0.8,
4.8+0.9 and 3.7+0.9 at 24h; with In-NS the same ratios
were 1.1+0.3, 1.2+0.7 and 0.7+0.2. These first results are
very encouraging and suggest that the same distribution
study should be carried out for therapeutic purposes by
replacing indium-iII with yttrium-90.
Absolute uptake of 1-131 HMFG2 monoclonal antibody
administered intraperitoneally in malignant and benign ovarian
tumours
J. Malamitsi, D. Skarlos, G. Aravantinos, P. Papakostas,
S. Vassilarou, A. Varvarigou, S. Fotiou, A.A. Epenetos &
C. Koutoulidis
NIMTS Hosp., Dimocritos, Athens, Greece.
J.R.F. Corvalan, W. Smith & V.A. Gore
Lilly Reseacrch Centre Limited, Eli Lilly, anld Co., ErI Wood
Matnor, WiJindlesham, Surrey, UK.
The functional properties of a hybrid-hybrid monoclonal
antibody recognising both CEA and vinca alkaloids have
been explored in vivo, in nude mice xenografted with MAWI,
a human colorectal tumour. The hybrid-hybrid monoclonal
localises specifically onto CEA expressing tumour tissue and,
furthermore, is able to target vinca alkaloids to it. Under the
influence of the hybrid-hybrid monoclonal, a profound
change in the biodistribution patterns of the vinca alkaloids
are observed. Therapeutic data produced in this in vivo
model indicated that treatment with vinca alkaloids in con-
juction with hybrid-hybrid monoclonal antibody is signifi-
cantly more effective in suppressing tumour growth of
established tumour xenografts than the alkaloids given as
free drugs.
Intraperitoneal injection of In-111-labelled monoclonal
antibodies in a nude mouse model intraperitoneally grafted
with a human ovarian cacrinoma
P. Thedrez, M. Kremer, C. Curtet, S. Pelhate,
C. Sai Maurel, J.C. Saccavini, D. Guerreau & J.F. Chatal
INSERM U211, Nantes, France.
Eight patients, 5 with known ovarian cancer (OC) and 3
with pelvic masses proven afterwards to be benign,
underwent immunoscintigraphy with 1-131 HMFG2. After
i.p. administration of 500-1500,uCi 1-131 HMFG2, biodistri-
bution of the antibody was studied. Biopsy material was
taken on a laparotomy and counted in a y-counter.
RESULTS
Pt.
no. Disease
I OC peritoneal
metastases
2 OC peritoneal
metastases
3 OC retroperitoneal
metastases
4 OC peritoneal
metastases-ascites
5 OC complete
remission
6 serous cyst
7 dermoid cyst
8 serous cyst
Absolute
uptake
% adii.
Immunoscan doseg-
+
±
+
0.1
0.13
0.0019
0.0008
(0.0275 ml ',
ascites)
0.0017
0.0011
0.0032
0.0016
The purpose of this work was to study the biodistribution of
several indium-I ll-labelled monoclonal antibodies with
known affinity for ovarian carcinomas in a nude mouse
model i.p. grafted with a human ovarian cancer (NIH:
OVCAR3). An immunohistochemical (immunoperoxidase)
study compared the reactivity of 3 antibodies - DF3, OC125
and HMFG2 - for the NIH: OVCAR3 cell line, by com-
In pts. I and 2, proven positive, absolute uptake was 100
times higher than that in pt 5, who was in complete
remission; 3, who had a single retroperitoneal metastasis and
6, 7 and 8, who had benign ovarian tumours. In pt 4,
however, with a rapidly reaccumulating ascites, very low
uptake was found in metastatic tissue, while higher uptake
values were found in the ascitic fluid.ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 519
Biodistribution, pharmacokinetics and imaging of 1-131
labelled OC125 in patients wirh ovarian carcinoma
H.J. Haisma, K.R. Moseley, A. Battaile, V.R. Zurawski &
R.C. Knapp
Depcar-tnwient of'Gnaecologic Oncologj, Dana Farber Cancer
Institute, Brighanm and Woman's Hospital and Harvard
Medical School, Boston, USA.
Fifteen patients with or suspect of having ovarian carcinoma
were injected i.v. or i.p. with 131-I labelled OC125 F(ab')2.
Immunoscintigraphy was performed at the time of injection
and at 24, 48 and 72 h after injection. Blood and urine
samples were used for pharmacokinetic studies. Biopsy
specimens were obtained at laparotomy and uptake of
antibody in selected tissue was calculated. Radioimmuno-
scintigraphy after i.v. injection revealed 50% of the tumour
sites. After i.p. injection all tumour sites were visualised,
except in one patient where the antibody stayed localised
because of adhesions. One patient with endometrial cancer
showed no specific uptake of the antibody after i.p. injection.
The serum half life of the radiolabelled antibody after i.v.
injection was 30 h. At 24 h after injection, 20% of the
injected dose remained 1-1 blood. After i.p. injection, there
was a slow appearance of radiolabelled antibody in the
blood with a maximum level of 1.4% dose 1-' at 24h after
injection. Urinary excretion of the radiolabel was the same
for both routes of administration, with 50% of the dose
excreted in 50h. Tumour uptake was 2.3 x 10-3% of injected
dose g-I tissue after i.v. injection and 4.8 x 10-3% of
injected dose g-1 tissue after i.p. injection. Liver and bone
marrow uptake was 2 x 10-3% injected dose g-1 tissue after
i.v. injection and <1 X 10-3% injected dose g- after i.p.
injection. I.p. administration of monoclonal antibodies in
ovarian carcinoma patients is preferred to i.v. injection both
for imaging and for specific uptake in tumour tissue.
Suppression of the anti-mouse antibody response to a
monoclonal antitumour antibody in rabbits with cyclosporin A
J.A. Ledermann, H.J. Begent, J.A. Boden, F. Searle &
K.D. Bagshawe
Canc-er Research Canmpaign Departmnent of Medical Oncology,
Chacring Cross Hospital, London W6 8RF, UK.
Single doses of radiolabelled antibody have not been
effective in eradicating tumours, so it is likely that patients
will require multiple doses for successful tumour therapy.
However, this cannot usually be given as most patients
develop anti-antibodies after one or two treatments. A
method has been developed to suppress the anti-antibody
response to repeated doses of a mouse monoclonal anti-
human chorionic gonadotrophin antibody. Rabbits injected
i.v. with 200pg antibody were given cyclosporin A (CsA),
20mgkg- 1, i.m. for 6 days starting at day 1. They were
rechallenged with antibody after 14 days under cover of
CsA. In some cases, antibody was ultracentrifuged to reduce
the immunogenicity due to microaggregates. In the animals
receiving CsA, the clearance of mouse antibody was signifi-
cantly prolonged and the rabbit anti-mouse antibody
response was absent in 8/8 given ultracentrifuged antibody
and 6/8 given the standard preparation. Ultracentrifugation
alone did not prevent the anti-antibody response. We are
now giving patients CsA and ultracentrifuged antibody to
prevent the formation of anti-antibodies to repeated doses of
radiolabelled monoclonal anti-CEA antibody used for the
therapy of advanced colorectal cancer.
Abstracts of Poster Exhibits
Monoclonal antibodies 123C3 and 123A8 identify a new
neuroendocrine marker.
D. Schol, S. Wagenaar & J. Hilgers
Division of Tumnour Biologj, The Netherlands Cancer
Ihstitute, 1066 CX Amsterdam, The Netherlands.
Monoclonal antibodies 123C3 and 123A8 were generated
against a crude preparation of membranes from a small cell
lung carcinoma (SCLC) specimen. Their tissue/tumour distri-
bution was identical. Western blot analysis showed an anti-
genic molecule at 29 kd, under reducing conditions. Non
reducing conditions revealed a band at - 150 kd.
In normal tissues, the antigen is present in neural and
neuroendocrine components like nerves, brain tissues and
certain epithelial populations such as Islands of Langerhans
and bronchial glands. In breast, thyroid and testis, positive
cells are scattered over the entire epithelium. The tumour
distribution also supports a putative neuroendocrine nature
of the antigens. Positive tumours include SCLC (25/25),
bronchial carcinoids (14/14); bronchial adenoid cystic
carcinomas (5/5) and medullary thyroid carcinomas (3/3).
Adenocarcinomas (26/27) and squamous cell carcinomas
(50/58) of the lung, follicular thyroid carcinoma (1/) and
carcinomas of the breast (6/8) are negative.
Both antigens can be demonstrated on the plasma
membrane of living cells. These data suggest that 123C3 and
123A8 define novel cell surface markers for neuroendocrine
differentiation.
Simultaneous demonstration of glia and glioma associated
antigens in human astrocytomas
T. Bilzer, D. Stavrou & B. Martin
Institut fur Tropoylhologie, Veterinastr 13, 8 Munchen 22,
FRG.
Glia fibrillary acidic protein (GFAP) and glioma associated
antigens (GAA) defined by monoclonal antibodies (McAbs)
were demonstrated simultaneously in human astrocytoma
tissue. GFAP was stained by PAP-method, GAA were
visualised by ABC-technique using alkaline phosphatase.
Fresh tumour samples from biopsy material were immedi-
ately frozen in liquid nitrogen and propagated in tissue
culture, respectively. Tumours were grafted to nude mice by
inoculation of 5 x 106 cells and cryosections were then taken
from primary and secondary tumours. For production of
McAbs against GAA, BALB/c mice were immunized with
whole glioma cells.
In both primary and secondary tumours, heterogeneity of
GFAP- and GAA expression was obvious. While GFAP was
restricted mostly to cell processes and less marked in the
perinuclear space, McAb-positive material was located either
in the tumour cell, surface membrane or cell processes. There
was remarkable expression of GAA in cell clusters which
failed to express GFAP. At higher magnifications, three
types of cellular reactivity were detected; (a) cells reacting
only with anti-GFAP, (b) cells reacting only with anti-GAA
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cells can be found in s.c. tumour grafts, they may represent
not only reactive cells, but also be part of the tumour cell
populations.
Immunocytological localisation of cancer-associated antigens
recognised by monoclonal antibodies using immunogold
techniques
R. Mandevile, M.G. Zelechowska, I. Ajdukovic,
A. Amarouch, S. Ghali, A. Hill & B. Grouix
Immunologi' Research Center, Institut Armand-Frappier
Universiti' of Quebec, Laval-des-Rapides (Quebec), Canada.
We have developed several monoclonal antibodies (MAbs)
that show a different spectrum of reactivity towards normal
and neoplastic breast cancer cells. These MAbs recognise
breast cancer-associated antigens expressed, either exclusively
(BCD-B4) or preferentially in the cytoplasm (BCD-E8) or on
the cell surface membrane (BCD-F9) of breast carcinoma.
Colloidal gold was utilised as a immunocytochemical marker
both at the light microscopic level using thin silver-enhance-
ment technique and at the electron microscope level using
thin sections and a modified protein-A gold technique.
Double labelling techniques using different size (l0nm and
2nm) probes were also employed on the same section of
breast tissue to simultaneously localise and compare the
reactivity of 2 MAbs. These techniques allowed us to
confirm our earlier immunohistochemical observations using
direct immunofluorescence and ABC techniques and to
further identify the subcellular localisation of our MAbs. We
believe that this rapid and accurate technique might prove to
be the method of choice for the visualisation of antigenic
sites at the light and electron microscope levels using MAbs.
Further development of these techniques may give further
qualitative and quantitative information on the distribution
of tumour-associated antigens within cells and tissues.
Plasma fibrin degradation products as a marker of ovarian
cancer
E.P. Lauraine, M.C. Mirshahi, J. Soria, C. Soria,
M. Mirshahi, R. Montalva, J.Y. Perrot, C. Boucheix,
T. Darse & A. Bernadou
Hotel Dieu, Par-is (4); INSERM U150, Paris and INSERM
U268 VillejuiJf France.
We examined the relationship between tumour proliferation
and activation of blood coagulation products. Blood acti-
vation results in the formation of fibrin which is degraded by
fibrinolysis producing fibrin degradation products (FDP).
Using an ELISA assay with a monoclonal antibody specific
for FDP, we studied FDP plasma concentrations in 50
patients with ovarian cancer.
In untreated patients, FDP levels correlated with
abdominal tumour size as measured by laparotomy and
CA125 assays. In 6/50 patients, however, only the FDP level
reflected the abdominal spread and thus was the best marker
with which to follow the evolution of these patients. On
chemotherapy, two groups of patients were examined com-
paring FDP levels with those of CA125. In group I (n= 14)
FDP levels acted as a tumour marker, since a good cor-
relation was found between the level of FDP and that of
CA125 and tumour size. In group 2 (n= 10), FDP levels
remained high, despite a significant decrease in CA125 levels
and in tumour volume. The ratio FDP/CA125 was at least 5
times higher than the initial ratio. Chemotherapy had a
similar toxicity in the 2 groups, but the response evaluated
by a second laparotomy was better in the patients of group 2
than in those of group 1 (complete remission was never
observed in the 14 patients of group 1, but was observed for
6/10 patients in group 2). Therefore, high levels of FDP in
patients on chemotherapy is associated with a better clinical
response. We hypothesise that, in group 2 patients, stimu-
lation of monocytes or macrophages by chemotherapy
(causing elevated FDP levels), may explain the better
response to chemotherapy.
The use of CA125 as a tumour marker for adenocarcinomas of
endocervix, endometrium and fallopian tube
A. Scharl, G. Crombach, H. Musch, M. Vierbuchen &
A. Bolte
Department of Obstetrics and Gynaecology, Institute of
Pathology, University of Cologne, FRG.
CA125 is a common constituent of the glandular epithelium
of the female genital tract. The clinical significance of CA125
as a tumour marker in carcinomas of the endocervix,
endometrium and fallopian tube was tested by immunohisto-
chemical detection of CA125 in 54 cancer tissues and by
radioimmunometric measurement of CA125 levels in 12
cancer cytosols and in serum samples of 60 patients with
recurrent carcinomas. Positive immunohistochemical staining
was present in 80% of the adenocarcinomas. In well
differentiated tumours the CA125 antigen was mainly con-
centrated at the apical poles of the cytoplasms and in the
luminal mucus. In poorly differentiated carcinomas a pre-
dominantly diffuse cytoplasmic staining was observed. At
least 35% of the cancer cells in each tissue section were
negative for CA125. In cancer cytosols of the endometrium,
the CA125 levels ranged from 173 to 13,215 U mg -I cell
protein. The CA125 serum concentrations were below the
cut-off value of 65 U ml - in 85% of patients with primary
cancer and in cases with positive immunohistochemical
staining and high cytosol levels. Elevated serum levels were
mainly observed in patients with advanced primary cancer
(stage III/IV; 30%) and recurrent carcinomas (79%).
Apparently, the release of the antigen into the circulation is
prevented by a tissue-blood-barrier, which has to be pene-
trated by a substantial quantity of infiltrative tumour tissue
and/or vessel invasion. Therefore CA125 may be a useful
tumour marker only in advanced carcinomas of the endo-
cervix, endometrium and fallopian tube.
Increased detection of micrometastases in the bone marrow of
patients with small cell lung cancer (SCLC)
F. Hay, A. Ford & R. Leonard
Imperial Cancer Research Fund Medical Oncology Unit,
Department of Haematology, University Department of
Clinical Oncology, Western General Hospital, Edinburgh
EH4 2XU, UK.
Rapid and accurate detection of metastases in the bone
marrow of patients with SCLC may have therapeutic impli-
cations. Analysis of bone marrow is done routinely by
conventional histological examination of marrow smears
which has a good detection rate where foci of tumour cells
are present or large numbers of cells infiltrate the marrow. It
is less satisfactory where single cells are sparsely distributed
throughout the marrow. We report on a series of 18 bone
marrows from patients with SCLC that were assessed for
tumour infiltration in several ways - routine histology;
cytospin preparations of red cell depleted marrow with
immunohistology using 2 MoAbs (HMFG2, CAM5.2);
detailed examination of multiple air dried preparations of
red cell depleted bone marrow with a panel of 10 SCLC-
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defined media (Hites). In 4/18 cases, the routine marrow
examination revealed tumour infiltration and in 6/18 of the
cytospin preparations tumour cells were seen. Using the
larger panel of MoAbs a further 9 cases were thought
suspicious of tumour involvement although only isolated
cells were detected. In 8/9 of these we sustained growth of
cells morphologically similar to the putative tumour infiltrate
in Hites medium for periods of 1-18 weeks, 2 remain viable
as established cell lines. These results indicate that detailed
analysis of bone marrow using a panel of MoAbs may be
worthwhile particularly in programmes utilising autologous
marrow rescue as intensification therapy.
Rhythmic oscillations of CEA levels in patients with breast
cancer
W. Jager, L. Wildt & W. Sauerbrei
Department ofGynaecology and Obstetrics, University of
Erlangen, FRG.
Previous studies using polyclonal anti-CEA antibodies
demonstrated considerable undulations of CEA serum levels
during a 24h period in patients with metastatic breast
cancer. This phenomenon was re-examined with an immuno-
radiometric assay applying 3 monoclonal anti-CEA antibodies
(CEA-ELISA, ID-CIS, Dreireich, FRG) for measurement
of the same serum samples. The coefficient of variation for
duplicate determinations in that assay system was always
below 5%. Hourly serum samples for CEA determination
had been obtained from 9 patients suffering from metastatic
breast cancer. Irrespective of the assay, the re-appearing
fluctuations of CEA serum levels could not be explained by
the variations caused by the assay. They seem to be an
inherent phenomenon of CEA secretion in that disease. Peak
concentrations could be detected every 4 to 6 h. These
rhythmic oscillations seem to be independent of cortisol and
prolactin levels, as well as of sleeping periods. The com-
parison of monoclonal and polyclonal measured CEA con-
centrations revealed parallel as well as opposing courses,
which might be explained by the heterogeneity of CEA.
Further studies should be done to evaluate if these rhythmic
oscillations are a unique property of CEA release from
cancer cells or a consequence of impaired metabolism and
clearance.
Demonstration of estramustine-binding protein in human lung
cancer cell lines using immunohistochemical and fast protein
liquid chromatography techniques
J. Bergh, J.E. Westlin, 0. Brodin, P.A. Bjork & S. Nilsson
Department of Oncology, University of Uppsala, Akademiska
Sjukhuset, S-751 85 and LEO Research Laboratories,
S-214 00 Helsingborg, Swveden.
The cytostatic drug estramustine used in the management of
prostatic carcinoma, binds in vivo to an intracellular protein,
the estramustine-binding protein (EMBP). This protein has
been previously isolated and characterised from rat ventral
prostate, and has also been discovered in human normal and
malignant prostatic tissues. In this study, we describe the
presence of EMBP in human lung cancer cell lines.
A panel of well characterised human lung cancer cell lines
was used, representing both the small (SCC) and non-SCC
group. A monoclonal antibody raised against the binding
protein was applied on frozen sections using the avidin-
biotin-peroxidase-antiperoxidase technique.
EMBP was demonstrated in 6/6 non-SCC cell lines. There
was heterogeneity and variability within the majority of these
cells. One important exception, the SCC cell line U-1906,
was homogeneously stained. The other three SCC cell lines
were negative. Furthermore, we have confirmed the presence
of EMBP in human lung cancer cell lines by fast protein
liquid chromatography.
These results form a basis for extended studies on biopsies
and on cell lines to clarify the mechanism of action of this
drug.
Selection of anti-carcinoembryonic antigen monoclonal
antibodies suitable for immunoscintigraphy and therapy
P. Seguin, J.C. Saccavini, B. Darbouret, F. Degorce,
J. Sertour & E.J.P. Jolu.
Conmpagnie Oris Industrie, BP 121, 91190 Gifsur Yvette,
France.
It is well known that monoclonal antibodies raised against
carcinoembryonic antigen (CEA) often cross react with other
related molecules such as NCA I and NCA II. Antibodies
intended for in vivo use should have high affinity and
specificity for CEA.
We have investigated 12 anti-CEA Mabs in order to select
those suitable for immunoscintigraphy and therapy. All
Mabs were IgG1 and the affinity constants ranged from 108
to 2.109 1M- 1. Epitopes on the CEA molecule were deter-
mined by binding inhibition of 125-1-labelled CEA on coated
Mabs. The antigenic mapping showed 6 different epitopes.
The cross reactions of the Mabs with the NCA molecules
(50 kd and 95 kd) were tested using an i25I-labelled antigen
preparation. Six Mabs showd no cross reactions: these
results were confirmed by binding of 1251-labelled Mabs on
isolated peripheral blood granulocytes.
Immunoperoxidase was carried out on a panel of normal
frozen tissues: colon, liver, pancreas, lung, skin, thymus and
tonsil. Five Mabs corresponding to 3 epitopes showed a
strict specificity. Most cross reactions involved granulocytes.
One Mab stained biliary ducts.
After iodination, Mabs were tested for their immuno-
reactivity: they were submitted to an immunoaffinity assay
using CEA coupled to Sepharose. The in vivo performances
of 3 Mabs recognising different epitopes on the CEA
molecule were compared in tumour bearing nude mice. The
immunoaffinity assay on CEA-sepharose was found to be a
good way to select Mabs suitable for in vivo use.
CA50. A useful tumour marker in monitoring patients with
colorectal cancer
B.E. Persson & J. Holmgren
Surgical Clinic 1, Sahlgeen' Hospital and Department of
Medical Microbiology, Universit.y of Goteborg, Goteborg,
Swveden.
Using a monoclonal antibody-based radioimmunoassay
inhibition method, we have determined pre-operative serum
levels of the carcinoma associated carbohydrate antigen
CA50 in 266 patients with primary colorectal cancer. CA50
levels exceeding the mean value for blood donor sera by
more than 2 standard deviations were found in 47% of these
patients. 15%, 430, 31% and 65% were elevated in patients
with Dukes A, B, C and D respectively. Only 5% of patients
with benign colorectal disease had elevated levels and these
were patients with ulcerative colitis of a duration of > 10yr.
Among patients who had developed a known recurrence
after operation for a primary Dukes' A-C colorectal cancer,
66% had elevated levels, 25% of resected patients with no
clinical evidence of disease after operation also had elevated
CA50 levels. From 139 patients operated for colorectal
cancer a definitive rise in CA50 was demonstrated in 12522 ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY
cases. Clinical evidence of recurrence developed in these
cases with lead times of CA50 titre rises ranging from 5-40
months. Our finding suggest that a rise in CA50 levels after
resection of a Dukes' A-C primary colorectal cancer is
indicative of a recurrence and may preceed clinical evidence
of disease by several months or even years. Thus CA50 may
be a useful tool for monitoring patients with colorectal
cancer.
Evaluation of tumour markers CA19-9, CA125 and CEA in
pancreatic cancer and other diseases
H.Y. Zhang
Department of Nuclear Medicine, Zhong Slhan Hospital,
Shanghai Medical Universi'y, Shanighai, Chiina.
We performed simultanc
markers CA19-9, CA125
follows:
A. Malignant disease:
pancreatic cancer
colorectal cancer
gastric cancer
cholangiocarcinoma
breast cancer
B. Benign disease:
pancreatic disease
gastrointestinal
disease
cholangeitis
total cell population. Using this model system we tested
several products that are supposed to reduce or eliminate
fibroblasts in mixed cultures: primary culture plates (Becton
Dickinson, 3847), putrescine (Janssen Chimica, 23-1400-1),
D-valine medium (Gibco, 041-2570), cytosine arabinoside
(Janssen Chimica 22.718.20), and genticin (Sigman, G5013).
Out of this series, genticin was the only product that was
able to selectively eliminate fibroblasts out of mixed cultures.
Evaluation of monoclonal antibody binding to human tumour
cells in immunocompetent animals using diffusion chambers
J.G. Fjeld, 0. Bruland, K. Nustad & H.B. Benestad
The Norwegian Radium Hospital, Oslo, and Inistitute of
Physiology, Uniiver-sity of Oslo, Norway.
eous measurements of tumour Preclinical studies of labelled antibodies for tumour imaging
and CEA. The results were as or immunotherapy are usually performed with the nude
mouse xenograft model. One main objection to this model is
that when the MoAbs are given to mice they are allogenic,
but xenogeneic when given to patients. Therefore, a novel
Frequency of positive results (%) method for preclinical MoAb evaluation which can be used
in any animal species has been developed. In this model the
CA19-9 CA125 CFA tumour is an i.p. diffusion chamber (DC), either filled with
cells or antigen-coated particles. The DC is made of 0.22,pm
23/25 10/25 12/25 micropore membranes and heat sealed to both sides of a
(92.0) (40.0) (48.0) plastic ring. The membranes allow diffusion of molecules,
12/61 8/61 16/61 while cells and particles are kept within the DC.
(19.6) (13.1) (26.2) In the first experiments, normal BALB/c mice were used 10*4 44 1to compare our DC system with results from nude mice. The
(25/0) (I0.0) (27.5) experiments were performed with the monoclonal H7 (a gift
(10.0) from T. Stigbrand) against placental alkaline phosphatase
8/11 3272 4/11 (PLALP) and two sarcoma-associated MoAbs (TP-1 and
(72.7) (27.2) (36.3) TP-3). The cell lines used were Hep2 (expressing PLALP),
0/23 5/23 4/23 and the osteosarcoma cell line OHS. Each mouse received
(0) (21.7) (19.3) two DC, one filled with a suspension of OHS, and one filled
with Hep2. After the implantation, the mice were random-
2/22 3/22 1/22 ised into groups, and each group was injected i.v. with one
(9.0) (13.6) (4.3) of the MoAbs (IgG or fragments) labelled with 125-1.
2/38 4138 II/38 Thereby, the two cell lines were mutually serving as antibody
(5.2) (10.5) (28.9) binding cells or controls. When intact IgGs were injected, *5.2) (10.5) (28.9) radioactivity ratios (DC cell suspension/blood) of 3-8 were 6320 3 20 4/20 achieved. With Fab or F(ab')2 fragments the ratios were
(30.0) (15.0) (20.0) higher, but the percentage of injected dose bound to the cell
was lower.
studies indicating that CA19-9
may be a useful marker for monitoring pancreatic
carcinoma.
Elimination of fibroblasts from mixed cultures of neoplastic
origin
T.W. Briers, T.M. Vandeputte, P.M. Stroobants,
E.J. Nouwen, R.L. Marynissen & M.E. De Broe
Department of Nephrologv -Hyper-tension, University, Hospital,
Antiwerp, Belgium.
The elimination of human fibroblasts from primary cultures
continues to be a major drawback in the use of in vitro
techniques. Most known methods, for the elimination of
normal proliferating fibroblasts from a mixed culture, e.g.
trypsinization, quick passage and mechanical elimination are
unsatisfactory. Our goal was to develop methods for the
elimination of fibroblasts, that are fast and reliable. We
selected a mixed cell culture of a permanent fibroblast cell
line, FLOW-4000 (human embryonic kidney, Flow Labora-
tories, 02-010) and HeLa-H21 cell line which expresses
alkaline phosphatase. The expression of alkaline phosphatase
was used to calculate the ratio of HeLa-H21 cells over the
Preclinical in vivo study with an anti-tumour monoclonal
antibody: Factors affecting radiolocalisation
M. Ripamonti, S. Canevari, M. Gadina, A. Turrin,
M. Gasparini, G.L. Buraggi & M.I. Colnaghi
Instituto Nazionale Tunmoti, Milan, Italy
An 131-I-labelled anti-CEA monoclonal antibody (Sorin
Biomedica F023C5), shown to detect neoplastic lesions by
radioimmunoscintigraphy (RIS) was tested in an animal
model prior to clinical therapeutic use. Nude mice bearing a
CEA producing human colon carcinoma received 131-I-
labelled anti-CEA F(ab')2 fragments. Comparison between
the RIS and specific activity (SA), i.e., the ratio of
cpm mg 1 in the tumour to the cpmmg-l in the blood,
muscle and kidney, showed that: independently of tumour
site (i.p. or s.c.) i.p. administered antibodies gave better SA
than i.v. RIS was negative. This could be attributed to an
instrumental limitation. Five per cent radioactivity remained
in the tumour with the i.v. injection, whereas up to 20%
radioactivity accumulated in the tumour and i.p. adminis-
tration. Data on repeated injections indicate a rise in tumour
uptake.
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In vitro targetting of normal and neoplastic B- and
T-lymphocytes using 111-Indium-labelled monoclonal
antibodies
1. Loutfi, R. Batchelor, J.P. Lavender & A.A. Epenetos
Department of Immunology, Diagnostic Radiology and
Clinical Oncology, Royal Postgraduate Medical School,
Hammersmith Hospital, London W12 OHS, UK.
Preliminary tests have been conducted in vitro using human
T- and B-cell lines as well as whole blood, to establish the
usefulness of two murine monoclonal antibodies, an anti-
CD5 and a Pan B, for radioimmunolocalisation and therapy.
Both monoclonal antibodies showed specificity for the cell
lines in question as tested by indirect immunofluorescence.
Radiobinding assays on cell lines and whole blood showed
binding of the 111-In-labelled antibody on up to 40% of
lymphocytes in whole blood. These results should permit
successful in vivo targetting of normal and neoplastic B- and
T-cells.
Optimization of imaging in relation to diethylene triamine-
pentaacetic acid anhydride (DTPA) labelling techniques
D.E.A. Zanin, P.F. Bruning, J. Hilkens & P. Hol
Netherlands Cancer Institute (Antoni van Leeuwenhoekhuis),
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Two monoclonal anti-MAM6 antibodies, designated 115D8
(IgG2b) and 140C1 (IgGl) have been labelled with Ill-In
via DTPA-chelation and assessed for localisation in human
ovarian carcinoma xenografts in nude mice.
DTPA was attached to the antibody in varying molar
ratios of 4:1, 8:1, 16:1, in order to determine the influence
of the DTPA-coupling on the in vivo distribution of the
MoAb. Following removal of the free DTPA on a sephadex
G25 column, 111-In-tropolonate was added to the DTPA-
MoAb. Unbound IIl-In was separated from the bound
fraction using a sephadex G25 column. The specific radio-
activity was kept the same in each study. Tumour bearing
nude mice, with comparable tumours, were injected i.p. and
imaged at several time intervals. The mice were then
dissected and the organs weighed and counted for radio-
activity. We found that superior images were obtained when
low DTPA:MoAb ratios were used and thus these labelling
conditions are recommended for clinical studies.
New prospects in the treatment of hepatocellular carcinoma
(HCC): 131-I lipidol, a promising agent?
P. Bourguet, J.F. Bretagne, J.L. Raoul, R. Duvauferrier, S.
Coornaert & J.Y. Herry
CHU Pontchaillou, 35033 Rennes, France.
The aim of this study was to assess the biodistribution and
therapeutic benefit of 131-iodine labelled Lipiodol in patients
with liver tumours.
Patients and methods. 42 patients aged 44-78 years, with
liver cirrhosis (10), liver metastasis (13) or HCC (19), were
investigated. Two ml of 131-I-labelled Lipiodol (70 MBq)
were injected into the hepatic artery via a Seldinger's
catheter. Scans were performed over the abdomen and the
thorax, 6h after injection and at days 4, 8, and 15. Eight
patients with metastasis and 7 with HCC received, 2-4 weeks
later, a second injection of 900-1600MBq of 1-131 Lipiodol.
Biodlistribution results: (1) in patients with metastasis and
HCC, there was no activity outside the liver and the lungs.
(2) 64% to 91% (median 82%) of the injected dose was
taken up by the liver after 6h. (3) For the HCC, the cpm
ratio of tumour to normal liver ranged from 2.4-6 (median
4.6). (4) The slopes of radioactivity decay were identical in
the normal liver and the lungs, but smaller in the tumour.
(5) The effective half life of 131-I Lipiodol ranged from 3.6-
10 days (median 4.6). (6) During an 8 day sampling period,
the iodine radioactivity in the urine was 30-50% (median
42%) of the injected dose. (7) Less than 10% of the injected
dose was found in the stool.
Therapeutic results: Clinical improvement was noticed in all
patients. A significant drop in serum levels of tumour
markers (CEA, CA 19.9 or AFP) was observed (>25% after
one week, >50% after 3 weeks); for the 3 patients with
HCC who survived more than 4 weeks, a significant
reduction in tumour size was observed.
Colony growth of phytohaemagglutinin stimulated peripheral
blood lymphocytes in patients with malignant melanoma
Z. Rudolf, G. Krosl & G. Sersa
The Institute ofOncology, Ljubljana, Yugoslavia.
Lymphocytes from peripheral blood in patients with malig-
nant melanoma were cultivated for 7 days using two-layered
cultivation method in semisolid medium. The ability of PHA
stimulated peripheral blood lymphocytes to form colonies
was tested in 43 patients with malignant melanoma and 15
healthy donors. In patients with malignant melanoma a
significantly lower colony count was observed when com-
pared to healthy controls (951 +581 vs. 1734+250; P<0.05).
The mean number of colonies in 10 patients with local
recurrence (575 +267) was lower than in 11 patients with
good response to treatment (1536+419) (P<0.05). In 7
patients with disseminated disease, the mean value of
colonies was 799 +480. A similar value was found in 10
patients receiving interferon treatment (557 +346). Both
groups were compared with a group of healthy donors and
patients responding to treatment and the differences were
found to be significant (P<0.05). In some patients the test
was repeated at different times in the course of the disease.
The number of colonies decreased with progression of the
disease, while the opposite was observed when response to
treatment was achieved.
Hybridoma screening for monoclonal antibodies to soluble
tumour antigens: Inadequacy of solid phase immunoassays
U. Auerswald, H. Kalthoff, W. Schmiegel & H.G. Thiele
Medizinische Klinik, Universitatskrankenhaus
Hamburg-Eppendorf, FRG.
Generation of monoclonal antibodies (mAbs) to human
gastrointestinal tumours often yields mAbs with carcino-
embryonic antigen (CEA) specificity. In an attempt to
develop a rapid and reliable strategy for detecting CEA
reacting hybridoma-supernatants (HS) at an early stage of
the screening process, we tried 3 different approaches: (1) HS
were screened by fluorescent immunoassay (FIA) with
purified CEA coated onto plastic wells. Forty-eight HS from
2,000 tested, were positive. (2) Fifty-three HS were tested
applying soluble, biotinylated CEA. Twenty-two were
positive, 5 of which were negative in the solid phase assay.
(3) Thirty-eight HS were tested in Western blot assay with
nitrocellulose bound CEA after SDS-PAGE. Eleven HS
showed a positive reaction, 8 of which had been positive in
solid phase FIA and solution based assay, 3 of them only in
solid phase assay. These data indicate that >50% of positive
results obtained by solid phase immunoassays are false
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latter system may fail to detect specific antibodies in some
cases. These findings suggest that a combination of different
assays is necessary to determine antibody specificity.
Monoclonal antibodies reacting with DMH induced rat
colorectal cancer
L. Baker, C. Yiu, M.J. O'Hare, B.A. Gusterson, L. Borman
& C.G. Clark
Department of Surgery, University, College London and
Institute Cancer Research, Sutton, UK and University of
Vermont, USA.
The dimethylhydrazine (DMH) induced colorectal cancer in
rat is a good model for the human disease. We have raised
mouse monoclonal antibodies to this tumour for targetting
studies. A crude membrane extract of the tumour from
Wistar rats or RCC2, a cell line derived from a Fischer
tumour transplant 4047 were used as immunogen. I.p.
immunisations were performed weekly until a humoral
response was detected. NSO parental cell was used as the
fusion partner. Immunoperoxidase staining on frozen
sections was used for antibody selection. Five antibodies
were obtained with 6 Wistar fusions. These were Lab 27.19
(IgM), Lab 22.1, Lab 22.10, Lab 3.3 (IgG2a) and Lab 26.15.
All antibodies react with the Wistar tumour and normal
colon. Lab 27 also reacts with the kidney, pancreas and the
Fischer transplant. The remaining antibodies react with most
epithelial cells and some with red blood cells. Four were
obtained with six RCC2 fusions. These were JB28.4 (IgG1),
JB39.4 (IgGl), JB2.6 (IgGI) and JB7.4 (IgM). All antibodies
react with the Fischer transplant, Wistar tumour and normal
colon. JB28.4 also reacts with the pancreas and Fallopian
tubes. The other antibodies react with various epithelial cells
and some with erythrocytes. These 4 antibodies show
positive immunofluorescence with live RCC2 cells. lodinated
JB28.4 binds with live RCC2 xells and in vivo tumour
localisation studies in the Fischer rat are currently under
way.
MRI after injection of specific NMR contrast agent Gd-25
DTPA-MAb, in nude mice bearing human colon
adenocarcinoma
C. Curtet, C. Bourgoin, J. Bohy, P. Thedrez & J.F. Chatal
INSERM U211, Faculty ofMedicine, Nantes; ORIS
Industrie, CEA Saclay, France
Monoclonal antibodies (MAbs) 19-9 and 73-3 specific for
human colon adenocarcinoma were labelled with a high
number of gadolinium atoms. Twenty-five DTPA were
chelated per MAb, with only slight loss of immunoreactivity.
The NMR contrast agent Gd-25, DTPA-MAb 19-9 or 73-3
([Gd] 17Mmol kg- 1, [MAb] 60,um) were injected into nude
mice bearing human colon adenocarcinoma (SW 948 or
HRT 18). Tumours were removed 24h after injection and TI
was measured in vitro with Bruker Minispec 20 MHz. Tl
relaxation time varied according to MAb specificity against
tumour targets. TI decreased 20% for MAb 19-9 and MAb
73-3 with SW948 tumour. Imaging was performed with this
model on Bruker Mini-Imager 4.7 teslas (Spin-echo, short
sequences, TR 500 ms, TE 30ms). Good contrast was
obtained 24h after Gd-25 DTPA-MAb injection.
Preparation and in vivo study of Yttrium-90 labelled
immunoconjugates
D. Snook, G. Rowlinson & A.A. Epenetos
Imperial Cancer Research Fund Oncology Group, Department
of Clinical Oncology, Royal Postgraduate Medical School,
Hammersmith Hospital, London W12 OHS, UK.
90-Yttrium has been suggested as a suitable isotope for
radioimmunotherapy. This pure beta emitter (max 2.3 MeV,
t1/2=64h) can be produced from a 90-Sr generator. The
monoclonal antibody HMFG1 and its F(ab')2 fragment were
coupled to DTPA using the bicyclic anhydride method. The
number of DTPA molecules per antibody was estimated and
immunoreactivity was tested by ELISA. 90-Y was reacted
with each conjugate at pH 6.0, 22 C for 2 h, giving specific
activities of 0.8-1.3uCiug-1 (81-91% labelling efficiency).
Immunoreactivity post-radiolabelling was assessed by ELISA
and RIA. Athymic nude mice received i.p. 14pg of either
HMFGI-DTPA-90-Y or HMFG1 F(ab')2 DTPA-90-Y.
Results were expressed as percentage injected dose g- 1 tissue
(%IDg-1). The blood activity peaked at 2h (20% IDg-1)
for both conjugates with a tl/2 of 39h and 14h for HMFGI
and F(ab')2 respectively. Over 3 days, liver, spleen and femur
activity increased while lung activity decreased for both
conjugates. Liver and femur activity were the same at 3 days
(12% IDg - for HMFG1, 10% IDg for F(ab')2). The
most significant differences were in kidney levels; 26%
IDg- for F(ab')2 by 3 days (20% IDg- 1 at 5 days)
compared with a constant 6% IDg-1 for intact IgG. Free
DTPA-90-Y injected i.p. was cleared via the kidneys to the
urine within 2h, as did free 90-Y but with some accumu-
lation in bone (32% IDg- 1 at 3 days). I.v. injected 90-Y
colloid accumulated in the liver (49% IDg-I at 24h) while
ip. 90-Y colloid remained in the peritoneum. Kinetic studies
such as these are a necessary prerequisite for selecting and
optimising antibody-guided irradiation.
Intraoperative tumour detection by radiolabelled antibodies
N. Pateisky, Ch. Schatten & K. Philipp
1st Department Obstetrics and Gynecology, University of
Vienna, A-1090, Austria.
Although radioimmunoscintigraphy (RIS) has progressed
rapidly over the last few years, tumours < I cm in diameter
cannot be diagnosed by RIS due to the limitations of
scintigraphic imaging. In an attept to improve this, we
developed a hand-held gamma ray detection probe for
intraoperative application. With this device it is now possible
to scan over the operation area during the surgical pro-
cedure. In this way, the probe can be brought into close
contact with questionable malignant tissue. This should
result in an enhanced sensitivity in the detection of small
tumour masses in contrast to conventional RIS. The results
achieved so far in a small number of patients (n=6) bearing
either colorectal or ovarian cancer confirmed this suggestion.
Possible applications of this method are: Isotope-guided
biopsies, assessment of completeness of resection, and
detection of tumour sites <1 cm.ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 525
Single photon emission computer tomography versus two
dimensional imaging with radiolabelled MoAbs in patients with
melanoma
D.E.A. Zanin, P.F. Bruning & J. Hilkens
Netherlands Cancer Institute (Antoni van Leeuwenhoekhuis),
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Thirteen patients with metastatic melanoma, were studied by
(gamma camera) radioimmunoscintigraphy. All patients
received i.v. 18-28 mCi 99'Tc-antimelanoma MoAb F(ab')2
and imaged after 6-8 h. Four patients were further studied at
18-24 h using Single Photon Emission Computer
Tomography (SPECT). Scans were performed with a
Siemens dualhead gamma camera. Both planar imaging and
SPECT detected malignant lesions in 11/13 (84%) patients.
In 4 patients we were able to detect lesions which were not
found by conventional diagnostic procedures. These lesions
were situated in the pelvis or abdomen and were confirmed
by follow-up. However, not all known lesions were detected,
especially small pulmonary metastases, because of high back-
ground activity in the cardiovascular system. The application
of SPECT improved the anatomical localisation of tumour
sites and gave a superior depth resolution resulting in more
true positives (3/4). This preliminary study indicates that
SPECT can improve the results of dimensional radiolabelled
MoAb distribution within an organ, provided very careful
quality controls are performed.
The pre-operative detection of clinical and subclinical lymph
node metastases in patients with breast cancer using
131-1-labelled HMFG2 and F(ab')2 fragments of HMFG1
A. Athanassiou, D. Pectasides, K. Pateniotis, L. Tzimis,
A. Lafi, D. Maintas, J. Taylor-Papadimitriou, A. Cross &
A.A. Epenetos
Metaxas Memorial Hospital, Piraeus, Greece and Imperial
Cancer Research Fund and Hammersmith Hospital, London,
UK.
In an attempt to pre-operatively detect clinical and sub-
clinical axillary lymph node metastases in patients with
breast cancer, we used the 131-I-labelled HMFG2 and
F(ab')2 HMFG1 monoclonal antibodies. We studied 10
patients with clinically obvious axillary lymph node disease
(group A), 10 patients with clinically negative axilla (group
B), using 131-I-labelled HMFG2 and 5 patients with
clinically negative axilla (group C), using 131-I-labelled
F(ab')2 HMFG1. All patients had clinical diagnosis of breast
cancer. Each patient received 1-1.5 mCi (specific activity
5mCi mg - protein) as a s.c. injection into the webs between
the 2nd and the 3rd fingers of both hands. The healthy side
was used as a control. The patients were scanned at 24 and
48 h after the injection. In group A, 7/10 patients had
positive scans. Histology and immunoperoxidase staining
confirmed the presence of tumour in the lymph nodes in all
patients.
In group B there were 4 true positive scans, 4 true
negative, 1 false positive (due to non-specific reaction) and 1
false negative. Histology and immunoperoxidase staining
showed lymph node involvement in 5 patients. In group C
there were 4 true negative scans and the histology confirmed
the absence of tumour in the axillary lymph nodes. In one
patient the radiolabelled antibody was arrested in the middle
of the right arm probably due to lymphatic obstruction,
although no clinically apparent lymphoedema was present.
These results indicate that this non-invasive approach can
pre-operatively detect tumour in axillary lymph nodes with a
high degree of accuracy and can be of value in the diagnosis
and staging of patients with breast cancer.
Monoclonal antibodies reactive with lung squamous cell
carcinoma. Cell reactivity and scintigraphic trial
L. Dazord, D. Bourel, B. Collet, P. Bourguet, J.C. Saccavini,
Ph. Delaval, B. Desrues & L. Toujas
CRLCC, CTS, CHU, Rennes, France and CEA, Saclay,
France
Po22, Po43, Po6O and Po66 mouse monoclonal antibodies
were produced by immunization against a human lung
squamous cell carcinoma. The tissue reactivity of antibodies
was monitored by immunoperoxidase staining of frozen or
paraffin sections. The antigens were studied by immuno-
precipitation and SDS gel electrophoresis. The antigen
immunoprecipitated by Po43 and Po6O from lung squamous
cell carcinoma appeared as a single band of a MW 70kd.
Po66 recognised an antigen with a relative MW 47-50 kd.
Purified monoclonal antibody Po66 and an unrelated IgG1
and immunoglobulin were labelled with radioactive iodine
and injected i.v. into nude mice bearing s.c. xenografts of
lung squamous cell carcinoma. The localisation index in the
tumour was 3.3. This allowed scintigraphic imaging of the
xenografts which were clearly outlined by days 9-11. Clinical
trials in progress suggest that the Po66 antibody will be
suitable for tumour imaging.
A controlled prospective immunoscintigraphic study in patients
planned for continuous regional chemotherapy of liver
metastases
R.P. Baum, M. Lorenz, C. Hottenrott, E. Staib-Sebler, G.
Hib-nauer, J. Happ & G. Hor
J. W. Goethe University Hospital, FrankJurt, FRG.
Continuous hepatic artery infusion chemotherapy (CHAI) of
liver metastases from colorectal cancer should only be
performed in patients (pts) without extrahepatic tumour.
However, the detection rate of small metastases outside the
liver by conventional diagnostic procedures is low. There-
fore, we used immunoscintigraphy (IS) in pts planned for
CHAI in an attempt to increase diagnostic accuracy.
Seven pts were injected with 62 MBq 1-131 labelled
F(ab')2 fragments of MAb 19-9/anti-CEA. Computer
acquisitions were recorded 2-13 days PI. IS was done
prospectively (i.e. without clinical/radiological information)
in 40 pts. The findings were compared to the distribution of
disease at subsequent surgery (and with CT scan/sono-
graphy) and confirmed by histology and immunohisto-
chemistry. Sensitivity of IS for liver metastases was 85%, for
extrahepatic abdominal disease 80%, and for pelvic re-
currences 91%. In 18%, IS was the only diagnostic method
to detect extrahepatic tumour involvement. In 51% IS was
complementary to CT/sonography. By immunoperoxidase
staining, 79% of tumours (n=42) were CEA, and 62% were
CA19-9 positive. Serum levels of CEA and/or CA19-9 (RIA)
were elevated in 82%.
We conclude that immunoscintigraphy can contribute
useful information in the pre-operative staging of pts
planned for regional chemotherapy.
Squamous cell carcinoma (SCC)-antigen in diagnosis and
therapy monitoring of cervical carcinoma
P. Stieber, P. Meier, W. Eiermann, B. Bayerl &
A. Fateh-Moghadam
Institute of Clin. Chem., Department Gynaecology Obstetrics,
Klinikum Gorbhadern, University ofMunich, FRG.
SCC-antigen is a tumour antigen (glycoprotein,
MW48,000Daltons) purified from squamous cell carcinoma
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of the uterine cervix. Preliminary results with a recently
developed immunoradiometric assay (ABBOTT) for the
determination of SCC in serum have shown it to be a good
marker in monitoring therapy of patients with cervical
squamous cell carcinoma. The assay proved to be linear over
the whole range of the calibration curve up to 150ngmml1.
Analytical recovery yielded between 75% and 94%. The
interassay co-efficient of variation (VK) at 3 different levels
was between 6.4 and 12.7%. The reference range based on
35 individuals (20-51 years) in whom neither clinical signs
nor laboratory results were suggestive of any disease,
covered 0.1-1.5ngml- 1 (cut off value: 2.Ongml- 1; mean
value: 0.61 ngml-1; median: 0.6ngml-1). One out of 15
patients with benign gynaecological disease had a slightly
increased SCC-level (CEA was below the cut-off level of
3 ngml-1). We determined SCC and CEA in 300 sera of 34
patients with cervical carcinoma. Twenty-one out of 34
patients showed elevated SCC-levels pre-operatively (74%),
whereas CEA was only elevated in 29%. Within a group of
patients with relapse or metastatic spread, we found in 71%
increased SCC levels (CEA 42%). Only one patient showed
an isolated elevated CEA value. Our results suggest that the
SCC-RIA is a useful tool in diagnosis and monitoring
therapy of cervical squamous cell carcinoma.
Clinical experience with radioimmunodetection (RID) using
anti-melanoma antibodies
Absorbed dose in skin from contamination with "'.In when
labelling
S.E. Strand, G. Grafstrom & B.A. Jonsson
Radiation Physics Department, University ofLund, Lund,
Sweden.
The radioisotope 111In is used in labelling of leucocytes,
granulocytes, platelets and antibodies. Because of its liquid
state there is always a risk of contamination during the
handling procedure; as the oxinate is soluble in fat, the
contamination may penetrate the skin. Emission of low-
energetic electrons during the decay would cause high
absorbed dose. The aim of this investigation was to evaluate
the 'normal' grade of contimination during labelling and the
absorbed dose encountered.
The degree of contamination during different labelling
procedures was investigated by determination of the activity
on protection gloves used by personnel. Measurable activity
remaining after all handling procedures ranged from 0.1 to
100kBk.
Leakage in different latex protection gloves, with or
without simulation of excessive sweating, showed fractions
up to one percent of contaminated activity. Penetration in
skin was evaluated with two different methods. Autoradio-
graphy and special measurements with a surface barrier
detector showed that the main activity stays on or near the
surface and not exceeding a depth of 10unm.
P. Oehr, A. Hotze, H. Biltz, W. Meinhof, U. Bull &
H.J. Biersack
Institute Nucl. Med., University Bonn and Department Nucl.
Med., University ofAachen, FRG.
Since 1985, the 99mTc-labelled monoclonal anti-melanoma
antibody (AB Technemab K, Sorin Biomedica, F(ab')2
fragments against the surface antigen 225.28S), was used in
RID studies. The present study reports results gained at two
centres. RID was performed in pts either with metastases of
a known primary lesion or in pts with unknown primary
lesion but proven metastases. 350pg of the antibody labelled
with 740MBq 99mTc were injected. Imaging was performed
on a large field gamma camera at various times from 1 h to
24h. Fifty pts with a total of 103 known metastases were
studied. These results of RID were then compared with
those obtained by clinical course, ultrasound, CT and/or
immunohistochemistry.
RESULTS:
True True False False
pos.* neg. pos. neg. Total
Pts [n] 21 (42%) 17 (34%) 2 (4%) 10 (20%) 50 (100%)
Lesions [n] 34 (33%) 18 (18%) 2 (2%) 49 (48%) 103 (100%)
*pos: in a patient=at least 1 lesion detected.
Pos. Neg.
pred. pred.
Sens. Spec. val. Acc. val. Preval.
Pts. 68% 89% 91% 76% 63% 62%
Lesions 41% 90% 50% 27% 81% 81%
Immunohistochemistry was positive in 9 out of 10 cases
studied. In 7 patients where the primary tumour was
undetectable by all other means, RID was also negative. We
conclude that in
- 30% of the pts studied, RID enabled
detection of hitherto unknown metastases.
Immunoscintigraphy of tumours before and after radiotherapy
P. Oehr, V. Bjorkland, B. Bjorkland, A. Bockisch &
H.J. Biersack
Nucleararmed University of Bonn, FRG and SBL, Stockholm,
Sweden.
This investigation was undertaken to evaluate the effect of
irradiation on the binding of monoclonal anti-TPA to
tumours during radioimmunodetection (RID). The mono-
clonal antibody 21 E4 against human tissue polypeptide
antigen (TPA) was radiolabelled with 125-I and injected into
animals with solid HeLa cell tumours (0.2-0.3g). For deter-
mination of uptake the animals were killed and tumours and
organs removed. The activity content of the organs was
calculated as gtissue- 1 uptake min- 1 to establish the
specific binding and the tumour/organ ratios. Scintigraphic
images were improved after irradiation and there was
increased uptake of radioactivity into the tumour which
might be dependent on the time delay after irradiation:
X-ray _ a +b +b
tumour weight 0.3g 0.3g 0.3g 0.2g
tumour/liver 1.7 5.4 3.8 4.3
tumour/lung 1.6 4.6 6.3 11.4
tumour/kidney 1.2 3.2 2.2 2.8
tumour/spleen 2.3 6.3 5.8 10.0
tumour/ileum 7.6 19.0 27.1 71.4
tumour/muscle 7.6 14.3 17.8 21.7
'I day after; b14 days prior to antibody injection.
RID after irradiation would be of interest for patients who
had undergone surgery and irradiation since remaining
tumour tissues might be detected.ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 527
CA19.9 and anti-CEA immunoscintigraphy in patients with
gastric, colorectal and pancreatic malignant tumours
J.R. Garcia-Talavera, M.A. Gomez, A. Sanchez, L. Ortega,
I. Rayo & J.G. Blancho
Servlicio Me(licina NuVclear, Hospital Clinico Universitario,
Salananca, Spain.
A group of 67 patients with gastro-intestinal tumours was
studied: (a) 30 had gastric cancer, (b) 27 had colorectal
cancer, (c) 5 had biliary or pancreatic cancer and (d) 5 had
cancer of othel origins. Eighty-six sites were affected: 45
primary, 18 loco-regional recurrences and 32 metastatic.
F(ab')2 fragmenits were used. Immunoscintigraphy was per-
formed 5 days after administration of 131-1 labelled anti-
body. Scintigraphy with 9(9mTc-radiocolloid and sometimes
With ()('Tc-HDP or 99"'Tc-O was carried out for anatomical
ref'ei-erece. Positive results were obtained in 25 patients in
group (a), 20 in group (b), 5 in group (c) and 4 in group (d).
Immiiunoscinitigraphy was positive in 65 of 86 sites repres-
enting a 75% overall sensitivity. Immunoscintigraphy was
positive in 87% of cases with elevated serum tumour
markers. It was also positive in 56% of patients with
negative ser-um tumour markers. The correlation between
immunloscintigraphy and serum tumour markers was 52%
for CEA and 61% for CA19.9. Three patients with no
evidence of tumour; 4 with benign pathology and 2 with
family history of gastric carcinoma were studied. Out of 9
patients had a positive immunoscintigraphy scan. We
conclude that CA19.9 and anti-CEA immunoscintigraphy
was useful in the detection of colorectal, pancreatic and
gastric carcinomas. This usefulness is not restricted to
patients with elevated serum tumour markers and can be of
interest also in patients with negative serum tumour markers.
Potentiation of anti-CEA immunotoxin by monoclonal
antibodies recognising different CEA epitopes
V.S. Byers, I. Pawluczyk, N. Berry, R.A. Robins &
R.W. Baldwin
Cancer Research Canmpaign Laboratories, Univeirsity of
Nottinighaitm, UK and Xnoma Corporation, Berkeley, CA 94710,
USA.
Immunotoxins containing ricin A chain (RTA) conjugated to
anti-CEA monoclonal antibodies are cytotoxic for tumour
cells expressing CEA and inhibit growth of human tumour
xenografts. Immunotoxin mediated cell cytotoxicity involves
multiple steps including target cell binding through the
antibody moiety and endocytosis of the bound conjugate.
The studies to be presented demonstrate that the cytotoxicity
was determined by in vitro assays with gastric carcinoma
MKN45 cells of an anti-CEA monoclonal antibody linked to
RTA is potentiated several-fold by antibodies recognising
separate epitopes on the CEA molecule. Flow cytometry
analysis of the binding of fluorescein iso-thiocyanate (FITC)
labelled anti-CEA antibody to gastric carcinoma MKN45
cells demonstrated that the dual treatment with second
antibody produced enhanced immunotoxin binding. Further-
more endocytosis of the anti-CEA antibody labelled with
tetramethyl rhodamine iso-thiocyanate (TRITC) on gastric
carcinoma cells was potentiated by the dual antibody. The
flow cytometry data suggest that the enhanced cytotoxicity
of RTA-immunotoxin by anti-CEA antibodies recognising
different epitopes reflects increased affinity of the antibody
moiety of the immunotoxins. This results in prolonged
retention of the immunotoxin on the tumour cells and so
increases product available for endocytosis. This leads to
increased cytotoxicity.
Monoclonal antibody 791T/36-ricin A chain immunotoxin in
the treatment of colorectal cancer
V.S. Byers, R. Rodvien, K. Grant & R.W. Baldwin
Xoma Corporation, Berkeley, CA 94710; Pacific Medical
Center, San Francisco, CA, USA and Cancer Research
Canmpaign Laboratory, Universitiy ofNottingham, UK.
Monoclonal antibody 791T/36 recognises a gp72 antigen
expressed upon colorectal carcinoma cells and has been used
extensively for imaging primary and metastatic colorectal
cancers. This has led to the design of an immunotoxin
containing ricin A chain (RTA) linked to the antibody via a
disulphide bond. The immunotoxin retains a high level of
antibody reactivity as determined by a competitive flow
cytometry assay. This compares the ability of immunotoxins
and free antibody to inhibit binding of fluorescein isothio-
cyanate-labelled 791T/36 antibody with 791T tumour cells.
Colony inhibition znd 75Se-selenomethionine-incorporation
assays demonstrate that the immunotoxin is cytotoxic in
vitro for tumour cells expressing the gp72 antigen. The
therapeutic efficacy of the immunotoxin has been demon-
strated by showing that it suppresses growth of human
tumour xenografts in athymic mice. Based upon these
findings and related animal toxicology studies, a phase I
clinical trial in patients with colorectal cancer has been
carried out.
Tumour associated antigens (TAA) and immunoscintigraphy
(I-131-Anti-CA19-9) during treatment of xenografts of
pancreatic carcinomas (PACA)
R. Klapdor, M. Bahlo & J.S. Kuhl
Ch. Ufe'r Medical Departm1ent, Unii'ersity of Hambuirg, FRG.
We have studied the secretion of TAA into the serum and
their cellular expression in 3 different human PACA xeno-
grafts during treatment with various modalities [chemo-
therapy, monoclonal antibodies (MAB), tumour necrosis
factor (TNF) and interferons (IFN)].
Treatment was for 3 weeks with: Mitomycin-C i.p., Mab
bw 494/32 or 17-1A 400pgday 1 and 300,000 U day given
i.p. For immunoscintigraphy (tumours of ISCH 84) we
injected lOOpCi I-131-anti-CEA 19-9 into the tail vein. The
results demonstrate that in the nude mouse model con-
comitant therapy may result in a significant decrease of TAA
in the serum correlating with decreasing tumour size in some
cases but also with tumour progression in other cases (HJ
84). This decrease of serum TAA does not necessarily
represent evidence of tumour regression. It was of interest
that different treatment modalities had a different effect on
circulating TAA (e.g. TNF induced a more marked decrease
of serum CA19-9 than mitomycin-C).
Immunotherapy of pancreatic carcinomas (PACA) with the
monoclonal antibody BW494/32
R. Klapdor, M. Bahlo, 0. Schwarzenbeck & M. Hirschmann
Meclical Department, Universit ofvHamburg, FRG.
BW 494/32 is a monoclonal antibody which might allow
treatment of PACA because of (a) positive ADCC in Cr-51-
release assay, (b) positive antigen expression by highly or
moderately differentiated PACA, (c) positive immunoscinti-
graphy with I-131-BW494/32 in patients as well as in xeno-
grafts in nude mice and (d) dose dependent inhibition of
tumour growth of xenografts. We studied 10 patients
suffering from advanced PACA: 8 male, 2 female, 44-73528 ADVANCES IN THE APPLICATIONS OF MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY
years of age. Six had prior chemo- or radiation therapy. Five
patients were treated with increasing doses up to a total of
150-210mg, and 5 with doses up to 500mg (30mgday -
after 100mg at day 1). Mab levels in serum were measured
during and after treatment as well as human anti-mouse
response (HAMA). Two patients had allergic reactions (I
after the 4th application, I after the 3rd cycle) but therapy in
general was well tolerated. Mab serum concentrations were
20-40 gml-1. All patients studied so far developed HAMA.
Two patients showed a significant decrease of CEA and in 1
case there was regression of liver metastasis and primary
tumour necrosis.
Immunotherapy of pancreatic cancer with the monoclonal
antibody BW 494/32 - preliminary results of a phase I/II
clinical trial
R. Kubel, M. Buchler, G. Schulz, K. Bosslet & H.G. Beger
Dep. General Surgery, University Ulm, and Behring Werke
AG, Marburg, FRG.
The hybridoma derived murine monoclonal antibody BW
494/32 was applied in a phase I/II clinical trial in passive
immunotherapy in patients with un-resectable pancreatic
cancer. This antibody was selected because of its ADCC
(antibody-dependent-cellular-cytotoxicity) reactivity against
established pancreatic cancer cells in vitro and its high
sensitivity and specificity for human pancreatic carcinoma
tissues as demonstrated by immunohistochemistry and
immunoscintigraphy. Between 5/86 and 2/87, 14 patients
with proven unresectable pancreatic cancer entered the
study. Postoperatively they received various dosages of
antibody i.v. - either in increasing dosages up to 300mg in 5
days (group I) or as a constant dosage at 3 day intervals up
to 300mg within 3 weeks (group II). All treated patients
were included in a follow-up program. Second-look
operations were performed in 3 cases. During primary
antibody therapy, 2 patients in group II required treatment
for severe allergic reactions, probably due to a human anti-
mouse response (HAMA), starting -2 weeks after the first
antibody application. Elevated HAMA levels could be
measured for months.
Out of 11 evaluable patients, 3 had a favourable clinical
course with evidence of 'stable disease'. One patient had no
evidence of tumour progression assessment second-look
operation 8 months after antibody administration. Eight
patients with high tumour load did not respond.
Criteria for the selection of patients with pancreatic cancer
who are suitable for immunotherapy have to be established.
HAMA response limits repeated antibody administration.
Preliminary biodistribution studies of monoclonal antibody
immunoconjugates
A.C. Perkins, M.V. Pimm, K.C. Ballantyne, J.D. Hardcastle
& R.W. Baldwin
Departments ofMedical Physics, Surgery and Cancer
Research, University Hospital, Nottingham, UK.
The use of monoclonal antibody-drug conjugates to selec-
tively increase the delivery of drug to tumours whilst
reducing whole body toxicity is currently being assessed.
Targetting studies are currently underway to assess the
tumour localisation and whole body biodistribution of the
anti-P72,000 dalton glycoprotein monoclonal antibody
791T/36 conjugated to cytotoxic drugs including metho-
trexate (MTX) and a plant-derived toxin.
Preliminary studies in mice with human tumour xenografts
have demonstrated the preferential localisation of radio-
labelled immunoconjugates. Tumour localisation of the
immunotoxin preparations has not been visualised and
accumulation of the toxin by the liver appears to be the
main problem although a therapeutic effect has been
observed in the mouse xenograft model.
Clinical imaging studies in 15 patients with colorectal
cancer injected with 70MBq 1-131-labelled 791T/36-metho-
trexate (200,ug antibody: 1.6,ug MTX) have demonstrated
that the biodistribution of the drug-conjugate is similar to
that of the unconjugated antibody. A T:NT uptake ratio of
2.9:1 has been measured from resected specimens. However,
an assay is being developed to determine the concentration
of drug in tumour and normal tissues.
Further clinical studies will be necessary to assess the
targetting ability of antibody-drug conjugates prior to their
use for tumour therapy.
Therapeutic strategies with biologically targetted radiotherapy
J.A. O'Donoghue & T.E. Wheldon
GIRO, Belvidere Hospital, Glasgow, UK.
Biologically targetted radiotherapy (BTR) with radiolabelled
antibodies or biochemical molecules such as MIBG has the
potential to improve the treatment of neoplastic disease. The
area where there is the greatest theoretical promise is in the
treatment of systemic disease where surgery or local radio-
therapy are not applicable. In common with other forms of
radiation therapy, the factor determining allowable radio-
nuclide doses will be the capacity of normal organs to
withstand radiation insult. Current experience with BTR
indicates that bone marrow is the dose-limiting organ. By
analogy with external beam total body irradiation (TBI) it is
expected that doses could be substantially increased by
incorporating bone marrow rescue (BMR) into treatment
protocols. Using the radionuclide 131-I it is anticipated that
a therapeutically advantageous biological heterogeneity
would be imposed by replacing one or more fractions of a
multifractionated TBI schedule by an appropriate amount of
BTR. Future development of BTR will probably involve the
use of alternative radioisotopes such as 90-Y and 211-At.
Mathematical model studies indicate that combination
TBI/BTR schedules incorporating BMR may be the optimal
strategy for treatment of systemic malignancy using these
radioisotopes.
Theoretical study of the possibility of biologically targetted
hyperthermia by hysteresis heating of antibody-linked magnetic
particles
J.A. O'Donoghue, T.E. Wheldon, H. Moseley & G. M. Ford
GIRO, Belvidere Hospital, Glasgow, UK.
The possibility of using metallic implants or injections of
ferromagnetic particles as a focus of heat generation by
oscillating magnetic fields of RF energy has been known for
some time. Difficulties associated with the injection of
material include possible toxicity of the material, non-
uniformity of dosing and the tendency for the materials used
to remain at the injection site. No biological specificity is
involved in any of the methods reported to date. A new type
of 'warhead' for antibody-guided cancer therapy may allow
biologically specific delivery of hyperthermia to tumour cells.
An example of this type of warhead is provided by the
monodisperse polymer particles incorporating a quantity of
magnetite which are presently used in bone-marrow purging
procedures. This approach has the theoretical advantage that
external 'activation' of the warhead is required which may
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mathematical model studies suggest that this concept is not
implausible in some circumstances. Significant heating of
very small conglomerations and particularly individual cells
is unlikely. The most suitable targets appear to be con-
glomerations of tumour cells of millimetre dimensions.
Though undeniably speculative, biological targetting of
hyperthermia seems worthy of further study using more
realistic mathematical models and experimental investigation
in vitro.
Immunotargetting in infective vis-ai-vis neoplastic lesions
D.K. Hazra, V. Lahiri, B.V.R. Elhence, K. Singh,
R.N.L. Srivanstava, I.P. Elhence, S. Saran,
J.P.K. Bhattacharjee, B. Arvind, S. Khandelwal, M. Kumari,
V.K. Rohtagi & R. Singh
S.N. Medical College, Agra, India.
Radioimmunotargetting in neoplastic lesions using mono-
clonal antibodies is closely paralleled by the use of such
antibodies in targetting infective lesions. The relative
problems in using these two models were studied using 125-I
labelled antimycobacterial tuberculosis antibodies WTB72
and WML34 and HMFG2 antibody in experimental models
(tuberculomas in normal Swiss albino mice and xenografted
human tumours in immunosuppressed mice). In infective
lesions the value of radioimmunotargetting is largely
diagnostic whereas for neoplasms both imaging as well as
therapy have to be considered. The latter involves considera-
tion of residence times in both tumour as well as in critical
organs. Successful radioimmunolocalization in tuberculous
lesions is especially significant in the Indian context where
tuberculomas form an important differential diagnosis of
neoplastic lesions. Radioimmunotargetting in infective
lesions may be easier than neoplastic lesions because tumour
cells are more likely to share antigens with normal tissues.
Radioimmunoscintigraphy (RIS) of ovarian cancer with Iodine
121 labelled F(ab')2 fragments of anti-CEA and OC125
G. Barzen, M. Langer, R. Becker, A. Mayer,
K. Koppenhagen & R. Felix
Raclio-Inmmuno-Scintigraphjy Group, Free University? ofBerlin,
FRG.
We are using an l-131 labelled cocktail of mg anti-CEA
and OC125 F(ab')2 fragments with a total activity of 80-
120 MBq (IMACIS 2/CIS-Isotope Diagnostic).
We investigated 30 patients after primary treatment of
ovarian cancer and 8 women preoperatively. Scanning was
done 1-7 days after application of the cocktail with SPECT
and planar technique. RIS was proven by CAT-Scan and
surgical means. We calculated the tumour to nontumour
tissue ratio (T/N) scintigraphy at the 6th day p.i.
In the follow-up 21 of 30 women had a relapse and/or
metastasis in the true pelvis. Eighteen had a true positive
scan. The T/N ratio was 1.6 and 2.2 (mean 1.8). Two
patients had a false positive scan, one proven pathologically
(Figo stage 3, RIS and biopsy after second look and
chemotherapy). Three scans were false negative, T/N ratio
1.3; 1.3; 1.4.
In 16 patients metastatic disease was found outside the
true pelvis. In 13 we found a true positive scan. The T/N
ratio was between 1.8 and 2.8 (mean 2.0). Three scans were
false negative (lung/liver/liver). Eight scans were false positive:
increased liver uptake (3), cyst in the liver (1), ascites (1),
increased paraaortic uptake (lymphnodes) (3) CAT-scan:
no disease.
RIS is a useful diagnostic tool in the follow-up
management of ovarian cancer; nevertheless the T/N ratio is
low.
The importance of low plasma CEA values in healthy smokers
for the sensitivity of CEA-assays in patients with cancer
P. Oehr
Inst. Nuclearmed, D-5300 Bonn, FRG.
The use of panels of monoclonal antibodies for plasma CEA
immunoassays enables further improvement of epitope speci-
ficity. As a result, an increased diagnostic sensitivity might
be achieved compared to immunoassays using polyclonal
antibodies. Three poly and 8 monoclonal CEA immuno-
assays were used simultaneously to determine the plasma
levels in healthy individuals (n = 149; 74 smokers and 75 non-
smokers) and patients with cancer (n=92). The results as per
assay were transformed into inverse distribution curves and
receiver operator characteristic (ROC) curves to determine
sensitivity and specificity of the assays. One of the mono-
clonal CEA tests showed a superior sensitivity compared to
all the other tests. Further analysis of the data revealed that
the improvement of discrimination was not due to increased
sensitivity but to better specificity in the control group. The
antibodies applied did not lead to as many elevated CEA
values for smokers as those of the other tests. This results in
a 100% increase of sensitivity compared to the other CEA
test kits. This shows that exclusion of 'false positive' CEA
values in the control group is important for increasing the
discrimination of CEA-assays.
Immunocytochemical detection of tumour cells in the bone
marrow of breast cancer patients at the time of primary
therapy
N. Harbeck, M. Untch & W. Eiermann
Frauenklinik im Klinikuni Grobhadern der LMU Munchen,
8000 Munchen 70, FDR.
Bone marrow aspirates from 45 patients and trephine
biopsies from 18 patients were taken at the time of primary
breast cancer therapy (stage TI-3, NO-2, MO-1). All
patients were screened for distant metastasis (X-ray,
bonescan).
Tumour cells in the bone marrow aspirates were detected
by immunohistochemistry using monoclonal antibodies
against EMA (epithelial membrane antigen) and LICR-
LON-M8 (kindly provided by the Ludwig-Institute, Sutton,
UK).
In 15/45 patients, bone marrow aspirate staining of
tumour cells (6-32 cells) could be demonstrated. Four of the
15 patients were at stage I, 9 at stage II, one at stage III and
one at stage IV disease at the time of clinical presentation.
In the 18 trephine biopsies, tumour spread could not be
detected. The median follow-up time was 13.1 months (min.
3 months, max. 27).
Eight of the 15 EMA-positive patients developed bone
metastases and also had visceral involvement. Two out of
the 30 EMA-negative patients developed local recurrence,
one visceral metastasis, and one bone metastasis. The median
time from bone marrow sampling to metastasis in EMA-
positive patients was 6.5 months. To detect the overall
survival rate longer follow-up periods and greater patient
numbers are required.
We conclude that bone marrow sampling can detect bone
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The nude rat heterotransplanted with human malignant
melanoma - an experimental model evaluating factors
influencing the kinetics of radiolabelled monoclonal antibodies
S.E. Strand, C. Ingvar & Norrgren
Radiation Physics Department, Surgery Department,
University ofLund, Lund, Sweden.
The nude rat, being larger, less sensitive and longer lived
than the nude mouse, offers advantages for studies of
tumours with radiolabelled monoclonal antibodies.
Nude rats (Rowett RNu/RNu) 2-3 months of age,
weighing 200-250 g were used. A human melanoma
metastasis (UM) maintaining strong expression of p97
melanoma-associated cell surface antigen was used. The
tumour was inoculated both s.c. and i.m. Monoclonal anti-
bodies 96.5, 2B2 and MG-21 as whole antibodies and
fragments and control antibody 1.4 have been used. The
antibodies were injected either iv. or s.c. To assess the blood
content in the tissues and to correct for circulating
antibodies red blood cells were labelled with 99-Tc-m.
Scintillation camera imaging was performed over one week
and animals were regularly dissected for specific organ
retention studies. This model has proven to be easier and
more useful to work with than the nude mouse model.
Antibody guided targetting of non small cell lung cancer using
Indium-l1l HMFGI-F(ab')2 fragments
H.P. Kalofonos, G. Sivolapenko, N. Courtenay-Luck,
D. Snook, G. Hooker, R. Winter, C.G. McKenzie,
J. Taylor-Papadimitriou, J.P. Lavender & A.A. Epenetos
ICRF Oncology Group, Department of Clinical Oncology,
Respiratory Unit, Medical Physics, Diagnostic Radiology,
Hammersmith Hospital and Imperial Cancer Research Fund,
London, UK.
Immunoscintigraphy using F(ab')2 fragments of tumour
associated monoclonal antibody HMFG1 was performed in
14 patients with primary and metastatix non-small cell
(NSCC) lung cancer. The antibody was conjugated with
DTPA and labelled with Indium-111.
All patients had significant concentration of Indium-1 11 in
the liver. No toxicity was encountered. No human anti-
murine-IgG antibody was detected in patients receiving 2
administrations of F(ab')2 fragments.
Localisation of all primary lesions and the majority (80%)
of metastatic lesions was achieved. Seven out of 14 patients
were also studied using an 111-In-labelled non-specific
antibody F(ab')2 fragments. In 3 patients, the uptake of the
non-specific antibody was significantly lower than that of
specific antibody (P<0.05). In the other 4 patients there was
no significant difference in the uptake between specific and
non-specific antibodies.
We conclude that although successful targetting of 111-In-
labelled F(ab')2 fragments of HMFG1 can be achieved in
patients with NSCC of lung, significant tumour localisation
can also be achieved using a non-specific antibody.
The use of CA-50 radioimmunoassay inhibition test in the
differential diagnosis of benign and malignant disease of the
breast, stomach and oesophagus
S.B. Kelly, M.J. Hersham, N.A. Habib, R.C.N. Williamson,
J. Spencer & C.B. Wood
University Department ofSurgery, Bristol Royal Infirmary,
Bristol, and Department ofSurgery, Royal Postgraduate
Medical School, London, UK.
This study investigated the role of the tumour marker CA-50
(carcinoma associated antigen) in the differential diagnosis
of benign and malignant disease of the breast, stomach and
oesophagus. Serum was collected from 50 controls, 24
patients with benign breast disease, 19 with benign
oesophago-gastric disease, 26 with breast carcinoma, 24 with
breast carcinoma, 24 with gastric carcinoma, and 21 with
oesophageal carcinoma. A radioimmunoassay (RIA) was
used to detect CA-50 in the serum and a level of 17 U ml-I
was used as a cut-off between benign and malignant disease.
All 50 normal subjects, 22 of 24 patients (92%) with benign
breast disease and 18 out of 19 (95%) with benign
oesophago-gastric disease had CA-50 levels below 17
Uml-1. In the cancer groups, 15 of 36 (42%) with breast
carcinoma, 18 of 24 (75%) with gastric carcinoma and 15 of
21 (71%) with oesophageal carcinoma had CA-50 levels
above 17Uml-1. Therefore in the breast group, the
sensitivity is 42% (15/36) and the specificity is 100% (50/50)
and 92% (22/24) for the control and benign groups respec-
tively. In the stomach and oesophageal group the sensitivity
is 73% (33/45) and the specificity is 100% (50/50) and 95%
(18/19) for the control and benign groups respectively. In the
group with breast carcinoma, there was no clear correlation
with clinical stage: 6/12 (50%) with stage I disease had CA-
50 levels >17Uml-1, 5/13 (39%) stage II, 1/4 (25%) stage
III and 3/7 (43%) stage IV. The data suggest that the CA-50
RIA test could be of-no use in the differential diagnosis of
benign and malignant diseases of the breast, stomach and
oesophagus.
Elevated serum HMFG-levels in breast and ovarian cancer
patients measured with a sandwich ELISA
P. Ashorn1, 0. Kallioniemi2, T. Hieranen3, R. Ashorn4 &
K. Krohn'
'Institute ofBiomedical Sciences, University of Tempere;
2Department of Clinical Chemistry, Tampere University
Central Hospital; 3Department ofObstetrics and Gynaecology,
Tampere University Central Hospital and 4Department of
Radiology, Tampere University Central Hospital, Finland.
HMFG antigen is a tumour-associated glycoprotein that has
been shown immunohistochemically to be expressed by
malignant cells in breast and ovarian and to a lesser degree
in gastrointestinal carcinomas. In this study we have
developed a non-isotopic sandwich ELISA for HMFG
antigen utilizing a polyclonal catcher and a monoclonal
tracer antibody. 52/52 healthy medical students had a serum
value <400 Uml-1 whereas 15/30 patients (50%) with
evidence of ovarian cancer and 13/37 (35%) with advanced
breast cancer had a value exceeding 400 Uml-1. 2/14 (14%)
patients with uterine cancer, 0/5 with cervical cancer, 0/5
with vulva carcinoma, 1/33 with gastrointestinal cancer, 0/4
with oesophageal cancer and 2/45 patients with leukaemia or
lymphoma had serum values below 400Uml-1. Progression
of ovarian cancer correlated with elevation of HMFG
antigen levels. Comparison of serum values of HMFG
antigens to CA125 and CA15-3 values showed that the
antigen detected by our assay is different from CA125 but
may be overlapping with CAl5-3 antigens.